Quinolone derivative or pharmaceutically acceptable salt thereof

ABSTRACT

[Problem] To provide a compound having excellent platelet aggregation inhibitory activity. 
     [Means for Resolution] It was found that quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R 0 )C(O)-lower alkylene-CO 2 R 0 , lower alkylene-CO 2 R 0 , lower alkenylene-CO 2 R 0 , —O-lower alkylene-CO 2 R 0 , —O-(lower alkylene which may be substituted with —CO 2 R 0 )-aryl or —O-lower alkenylene-CO 2 R 0  (wherein R 0  is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. In addition, it was confirmed that these quinolone derivatives also have excellent platelet aggregation inhibitory activity. Based on the above, these quinolone derivatives or pharmaceutically acceptable salts thereof are useful as platelet aggregation inhibitors.

TECHNICAL FIELD

The present invention relates to a pharmaceutical, particularly a novel quinolone derivative or a pharmaceutically acceptable salt thereof, which is useful as a platelet aggregation inhibitor or a P2Y12 inhibitor.

BACKGROUND OF THE INVENTION

Since the discovery by Donne et al. in 1842, blood platelets have been regarded for a long time as a component of blood necessary for hemostasis. Nowadays, it has been revealed that platelets not only simply play the leading role in the hemostatic mechanism but also show clinically noteworthy multifunctional properties such as concern in the realization of arteriosclerosis, circulatory organ diseases including thrombotic diseases, metastasis, inflammation, rejection reaction after transplantation and immune reaction.

In general, therapies for blood reperfusion with pharmaceutical agents or physical methods have been carried out for thrombotic diseases and ischemic diseases. However, a phenomenon in which activation, adhesion and aggregation of platelets are accelerated after carrying out revascularization due to breakdown of vascular tissues including endothelial cells, or collapse of fibrinolysis-coagulation balance or the like caused by the drug itself, has recently been found and causing clinical problems. For example, it has been revealed that after recirculation by a thrombolytic therapy using t-PA or the like, fibrinolysis ability and coagulation ability are activated and systemic coagulation-fibrinolysis balance collapses. Clinically, it results in re-obstruction which has been causing a therapeutically large problem (Non-patent reference 1).

On the other hand, a PTCA therapy or a stent indwelling method has been rapidly popularizing and gaining a certain fruit for the treatment of diseases based on angina pectoris, myocardial infarction and the like coronary artery stricture and aorta stricture. However, since these therapeutic methods damage vascular tissues including endothelial cells, acute coronary obstruction, and further re-stricture which occurs at chronic stage, has been causing problems. Platelets are taking an important role in various thrombolytic ill effects (re-obstruction and the like) after such a revascularization. Thus, effectiveness of an anti-platelet agent is expected, but sufficient effects of the conventional anti-platelet agents have not been confirmed.

As preventive or therapeutic agents for such circulatory organ system diseases, aspirin, cilostazol, prostaglandin I₂, prostaglandin E₁, ticlopidine, clopidogrel, dipyridamole and the like platelet aggregation inhibitors have been used. Also in recent years, a GPIIb/IIIa antagonist which inhibits the final step of platelet aggregation and has strong platelet aggregation inhibition activity has been developed, but its use is limited to the intravenous drip infusion at thrombosis acute phase (Non-patent reference 2).

In recent years, it has been revealed that, regarding ticlopidine and clopidogrel which are used as anti-platelet agents, these are exerting platelet aggregation inhibitory activity through the inhibition of P2Y12 as an ADP receptor by their active metabolites. Thereafter, a triazolo[4,5-D]pyrimidine derivative (Patent reference 1), piperazine and/or homopiperazine derivatives (Patent Reference 2 and Patent Reference 3), a pyrazolidinedione derivative (Patent Reference 4), an isoquinolinone derivative (Patent Reference 5) and the like have been reported as compounds having P2Y12 inhibitory activity.

On the other hand, Patent References 6 and 7 are known as quinolone derivatives.

In Patent Reference 6, a compound represented by a formula (A) having antimicrobial action is known, but possession of platelet aggregation inhibitory activity by these derivatives is not known. In addition, its structure is different from the compound of the present invention in terms that the moiety which corresponds to R⁵ of the compound of the present invention is a carboxylic acid, ester or carbamoyl.

(In the formula, R¹ represents —OR⁹, amino group or lower alkylamino group, and R9 hydrogen atom or a carboxy-protecting group. See said official gazette for other symbols.)

In Patent Reference 7, it is reported that a compound represented by a formula (B) has P2Y12 inhibitory activity. However, its structure is different from the compound of the present invention in terms that the moiety which corresponds to R⁵ of the compound of the present invention is carbamoyl.

(See Said Official Gazette for Symbols in the Formula.)

In Patent Reference 8, it is reported that a compound represented by a formula (C) has P2Y12 inhibitory activity. However, its structure is different from the compound of the present invention in terms that the moiety which corresponds to R⁵ of the compound of the present invention is carbamoyl.

(See Said Official Gazette for Symbols in the Formula.)

Non-patent reference 1: “Journal of American College of Cardiology”, 1988, vol. 12, p. 616-623 Non-patent reference 2: “Sogo Rinsho (Synthetic Clinic)”, 2003, vol. 52, p. 1516-1521

Patent Reference 1: International Publication WO 00/34283 Patent Reference 2: International Publication WO 02/098856 Patent Reference 3: International Publication WO 03/022214 Patent Reference 4: International Publication WO 05/000281 Patent Reference 5: International Publication WO 05/035520 Patent Reference 6: International Publication WO 98/23592 Patent Reference 7: International Publication WO 05/009971 Patent Reference 8: International Publication WO 06/077851 DISCLOSURE OF THE INVENTION Problems that the Invention is to Solve

Under such a situation, it is strongly desired to develop an anti-platelet agent with a high safety profile with a smaller adverse bleeding effect and with distinct pharmaceutical efficacies at not only acute phase but also chronic phase. Thus, it is an object of the invention to develop a platelet aggregation inhibitor or a P2Y12 inhibitor having a high pharmacological effect and a good balance between the pharmacological effect and the safety profile.

Means for Solving the Problems

Accordingly, the present inventors have conducted intensive studies with the aim of overcoming the above-mentioned problems and, as a result, found that a novel quinolone derivative has excellent platelet aggregation inhibitory activity or P2Y12 inhibitory activity and has excellent pharmacokinetics, and thereby accomplished the present invention.

That is, the present invention relates to a quinolone derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof

[Symbols in the formula represent the following meanings, R¹: cycloalkyl or lower alkylene-cycloalkyl, wherein cycloalkyl in R¹ may be substituted, R²: —H or halogen, R³: —H, halogen, —OR⁰ or —O-lower alkylene-aryl, R⁰: the same or different from each other and each represents —H or lower alkyl, R⁴: lower alkyl, halogeno-lower alkyl, lower alkylene-cycloalkyl, cycloalkyl or heterocyclic group, wherein cycloalkyl and heterocyclic group in R⁴ may respectively be substituted, R⁵: —NO₂, —CN, lower alkyl, lower alkenyl, halogeno-lower alkenyl, -L-R^(a), —C(O)R⁰, —O—R^(b), —N(R⁶)₂, lower alkylene-N(R⁶)(R^(c)), —N(R⁶)C(O)—R^(d), lower alkylene-N(R⁶)C(O)—R^(d), lower alkylene-N(R⁰)C(O)O-lower alkyl, —N(R⁰)C(O)N(R⁰)—R^(e), lower alkylene-N(R⁰)C(O)N(R⁰)—R^(e), —N(R⁰)S(O)₂N(R⁰)C(O)—R^(d), —CH═NOH, cycloalkyl, heterocyclic group, (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl or (4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl, wherein cycloalkyl and heterocyclic group in R⁵ may respectively be substituted, R⁶: H, lower alkyl, lower alkylene-CO₂R⁰ or lower alkylene-P(O)(OR^(p))₂, wherein lower alkylene in R⁶ may be substituted, L: lower alkylene or lower alkenylene which may respectively be substituted R^(a): —OR⁰, —CN, —O-lower alkylene-aryl, —O-lower alkylene-CO₂R⁰, —C(O)R⁰, —CO₂R⁰, —C(O)NHOH, —C(O)N(R⁶)₂, —C(O)N(R⁰)-aryl, —C(O)N(R⁰)—S(O)₂-lower alkyl, —C(O)N(R⁰)—S(O)₂-aryl, —C(O)N(R⁰)—S(O)₂-heterocyclic group, —NH₂OH, —OC(O)R⁰, —OC(O)-halogeno-lower alkyl, —P(O)(OR^(p))₂, aryl or heterocyclic group, wherein aryl and heterocyclic group in R^(a) may be substituted, R^(p): R⁰, lower alkylene-OC(O)-lower alkyl, lower alkylene-OC(O)-cycloalkyl, lower alkylene-OC(O)O-lower alkyl, lower alkylene-OC(O)O-cycloalkyl, or lower alkylene-heterocyclic group, wherein heterocyclic group in R^(p) may be substituted, R^(b): H, cycloalkyl, aryl, heterocyclic group, lower alkylene-R^(ba) or lower alkenylene-R^(ba), wherein lower alkylene, lower alkenylene, cycloalkyl, aryl and heterocyclic group in R^(b) may be substituted, R^(ba): —OR⁰, —O—Si(lower alkyl)₃, —CO₂R⁰, —C(O)NHOH, —C(O)N(R⁰)₂, —C(O)N(R⁰)—S(O)₂-lower alkyl, —C(O)N(R⁰)—S(O)₂-aryl, —C(NH₂)═NOH, —C(NH₂)═NO—C(O)R⁰, —C(NH₂)═NO—C(O)-lower alkylene-C(O)R⁰, —CO₂-lower alkylene-aryl, —P(O)(OR^(p))₂, —C(O)R⁰, —C(O)-aryl, cycloalkyl, aryl or heterocyclic group, wherein aryl and heterocyclic group in R^(ba) may be substituted, R^(c): H, lower alkyl, lower alkylene-OR⁰, lower alkylene-CO₂R⁰, lower alkylene-C(O)NHOH, lower alkylene-C(O)N(R⁰)₂, lower alkylene-P(O)(OR^(p))₂, lower alkylene-aryl, lower alkylene-heterocyclic group, aryl or heterocyclic group, wherein lower alkylene, aryl and heterocyclic group in R^(c) may be substituted, R^(d): C₁₋₇ alkyl, lower alkenyl, halogeno-lower alkyl, lower alkylene-R^(da), lower alkenylene-R^(da), cycloalkyl, aryl or heterocyclic group, wherein lower alkylene, lower alkenylene, cycloalkyl, aryl and heterocyclic group in R^(d) may be substituted, R^(da): —CN, —OR⁰, —OC(O)R⁰, —O-lower alkylene-CO₂R⁰, —O-aryl, —CO₂R⁰, —C(O)NHOH, —C(O)N(R⁰)₂, —CO₂-lower alkylene-N(R⁰)₂, —P(O)(OR^(p))₂, —N(R⁶)₂, —N(R⁰)C(O)R⁰, —C(O)N(R⁰)-aryl, —C(O)N(R⁰)-(lower alkylene which may be substituted with —CO₂R⁰)-aryl, —N(R⁰)C(O)-aryl, —N(R⁰)C(O)—OR⁰, —N(R⁰)C(O)—O-lower alkylene-aryl, —N(R⁰)S(O)₂-aryl, —S-heterocyclic group, —C(O)N(R⁰)-heterocyclic group, —N(R⁰)C(O)-heterocyclic group, cycloalkyl, aryl or heterocyclic group, wherein cycloalkyl, aryl and heterocyclic group in R^(da) may be substituted, R^(e): lower alkylene-CO₂R⁰, lower alkylene-C(O)NHOH, lower alkylene-C(O)N(R⁰)₂, lower alkylene-heterocyclic group, aryl, heterocyclic group, —S(O)₂-aryl or —S(O)₂-heterocyclic group, wherein aryl and heterocyclic group in R^(e) may be substituted,

X: CH or N, A: C(R⁷) or N,

R⁷: —H and lower alkyl, or R⁴ and R⁷ may together form lower alkylene which may be substituted, with the proviso that 7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile is excluded. The same shall apply hereinafter.]

In addition, this application relates to a pharmaceutical, particularly a P2Y12 receptor inhibitor and/or a platelet aggregation inhibitor, which comprises a quinolone derivative represented by the general formula (I) or a salt thereof as the active ingredient.

Further, this application also relates to the use of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a P2Y12 receptor inhibitor and/or a platelet aggregation inhibitor, and to a method for treating a circulatory organ system disease closely related to the thrombus formation by platelet aggregation, which comprises administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to a patient. That is, (1) a pharmaceutical composition which comprises a compound described in the general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

(2) The pharmaceutical composition of (1) which is a platelet aggregation inhibitor. (3) The pharmaceutical composition of (1) which is a P2Y12 inhibitor. (4) Use of a compound described in the general formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a platelet aggregation inhibitor or a P2Y12 inhibitor.

EFFECT OF THE INVENTION

Since the compound of the present invention has excellent platelet aggregation inhibitory activity or P2Y12 inhibitory activity, it is useful as a pharmaceutical, particularly a platelet aggregation inhibitor or a P2Y12 inhibitor. Accordingly, the compound of the present invention is useful as a preventive and/or therapeutic agent for a circulatory organ system disease closely related to the thrombus formation by platelet aggregation, such as unstable angina, acute myocardial infarction and its secondary prevention, re-obstruction and re-stricture after hepatic artery bypass surgery, PTCA operation or stent indwelling operation, hepatic artery thrombolysis acceleration and re-obstruction prevention and the like ischemic diseases; transient cerebral ischemic attack (TIA) cerebral infarction, subarachnoid hemorrhage (vasospasm) and the like cerebrovascular accidents; chronic arterial occlusive disease and the like peripheral arterial diseases; and the like, and as an auxiliary agent at the time of cardiac surgical operation or vascular surgical operation.

BEST MODE FOR CARRYING OUT THE INVENTION

The following describes the present invention further in detail.

In this description, the “lower alkyl”, “lower alkenyl”, “lower alkylene” and “lower alkenylene” respectively mean hydrocarbon chains having from 1 to 6 carbon atoms which maybe in the straight chain or branched chain form, unless otherwise noted.

Accordingly, the “lower alkyl” means a C₁₋₆ alkyl, and illustrative examples thereof include methyl, ethyl, propyl, butyl, pentyl or hexyl, or structures isomers thereof such as isopropyl, tert-butyl or the like, preferably a C₁₋₅ alkyl, more preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or 3-pentyl.

The “lower alkenyl” means a C₂₋₆ alkenyl, and it may have two or more double bonds. Illustrative examples thereof include ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl and the like, of which preferred is a C₂₋₃ alkenyl and more preferred is ethenyl or propenyl.

The “lower alkylene” means a divalent group in which one hydrogen is removed from an optional position of the “lower alkyl”, and is illustratively methylene, methylmethylene, ethylene, propylene, butylene or the like, preferably a C₁₋₄ alkylene, more preferably methylene, methylmethylene, ethylene or propylene.

The “lower alkenylene” means a divalent group in which one hydrogen is removed from an optional position of the “lower alkenyl”, and is illustratively vinylene, propenylene, butenylene or the like, preferably a C₂₋₃ alkenylene, more preferably vinylene, propenylene.

The “halogen” means a monovalent group of halogen atom, and fluoro, chloro, bromo, iodo or the like may be cited illustratively, of which fluoro or chloro is preferred.

The “halogeno-lower alkyl” means a group in which at least one optional hydrogen atom of the aforementioned “lower alkyl” is substituted with the aforementioned “halogen”, and illustrative examples thereof include trifluoromethyl, trifluoroethyl or the like, of which trifluoromethyl is preferred.

The “halogeno lower alkenyl” means a group in which at least one optional hydrogen atom of the aforementioned “lower alkenyl” is substituted with the aforementioned “halogen”, and illustrative examples thereof include fluorovinyl, chlorovinyl or the like.

The “cycloalkyl” means a C₃₋₁₀ non-aromatic hydrocarbon ring, and it may form a bridged ring or a spiro ring, partially have an unsaturated bond or be condensed with benzene ring. However, when benzene ring is condensed, the linking hand is present on the non-aromatic ring. Illustrative examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclohexenyl, cyclooctanedieneyl, adamantly, norbornyl, indanyl having a linking hand at from the 1- to 3-position and the like. Preferred is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and more preferred is cyclopentyl or cyclohexyl.

The “aryl” means a monocyclic to tricyclic C₆₋₁₄ aromatic hydrocarbon ring, and illustrative examples thereof include phenyl, naphthyl or the like, of which phenyl is preferred. In addition, a C₅₋₈ cycloalkyl ring may be condensed. However, when a cycloalkyl ring is condensed, the linking hand is present on the aromatic ring. For example, it may form indanyl having a linking hand at from the 4- to 7-positions, or tetrahydronaphthyl having a linking hand at from the 5- to 8-positions.

The “hetero ring” is a general name which includes “aromatic hetero ring” and “non-aromatic hetero ring”. The “aromatic hetero ring” means a monocyclic aromatic hetero ring which is a monocyclic 5- to 7-membered aromatic group containing from 1 to 4 of the same or different hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur, a bicyclic aromatic hetero ring in which monocyclic aromatic hetero rings are condensed or a monocyclic aromatic hetero ring is condensed with benzene ring, or a tricyclic aromatic hetero ring in which a bicyclic aromatic hetero ring is condensed with a monocyclic aromatic hetero ring or benzene ring. Illustrative examples thereof include pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, furazanyl, pyridyl, pyranyl, thiopyranyl, pyridazinyl, pyrimidinyl, pyrazyl, indolyl, isoindolyl, indolizinyl, benzofuryl, benzothienyl, benzoimidazolyl, indazolyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazonyl, quinolyl, isoquinolyl, chromenyl, benzothiopyranyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, benzodioxolyl, benzodioxinyl, benzodioxepinyl, carbazolyl and the like, and the nitrogen atom and/or sulfur atom constituting these rings may be oxidized. In addition, these rings may be partially saturated. Preferred is pyridyl, furyl, thienyl, indolyl or quinolyl.

The “non-aromatic hetero ring” means a saturated or partially saturated monocyclic 3- to 10-membered, preferably 5- to 7-membered, monocyclic non-aromatic hetero ring which contains from 1 to 4 hetero atoms selected from O, S and N, a bicyclic non-aromatic hetero ring in which monocyclic non-aromatic hetero rings are ring-condensed or a monocyclic non-aromatic hetero ring is ring-condensed with a monocyclic non-aromatic hetero ring, a C₅₋₈ cycloalkyl ring, benzene ring or an aromatic hero ring, or a tricyclic non-aromatic hetero ring in which a bicyclic non-aromatic hetero ring is ring-condensed with a C₅₋₈ cycloalkyl ring, benzene ring or an aromatic hero ring. These may form oxide or dioxide trough the oxidation of the S or N as the ring atom or may form a bridged ring or a spiro ring. Illustrative examples thereof include hydropyridyl, dihydropyrrolyl, dihydrooxazolyl, dihydrothiazolyl, dihydroimidazolyl, piperidyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrazolidinyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, azepanyl, homopiperazinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrimidinyl, chromanyl, dioxoranyl, homomorpholinyl and the like. Preferred is pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.

The term “may be substituted” means “not substituted” or “substituted with the same or different 1 to 5 substituent groups”.

In the specification, the substituents acceptable as those for the phrase “which may be substituted” satisfactorily include those for routine use in the art as substituents for the individual groups. In addition, when two or more groups are present like the case of the R⁰ of —N(R⁰)₂, respective groups may be the same or different from each other.

As the acceptable substituent group of the “lower alkylene” which may be substituted in R⁶, halogen may preferably be cited.

Preferably, a group selected from the following group G¹ may be cited as the acceptable substituent group of the “lower alkylene” and “lower alkenylene” which may be substituted in L; the “lower alkylene” and “lower alkenylene” which may be substituted in R^(b); the “lower alkylene” which may be substituted in R^(c); the “lower alkylene” and “lower alkenylene” which may be substituted in R^(d); and the “lower alkylene”, formed by R⁴ and R⁷, which may be substituted.

Group G¹: halogen, —OR⁰, —CO₂R⁰ and —CO₂-lower alkylene-aryl.

Preferably, a group selected from the following group G² may be cited as the acceptable substituent group of the “cycloalkyl” which may be substituted in R¹; the “cycloalkyl” which may be substituted in R⁴; the “cycloalkyl” which may be substituted in R⁵; the “cycloalkyl” which may be substituted in R^(b); the “cycloalkyl”, which may be substituted in R^(d); and the “cycloalkyl”, which may be substituted in R^(da).

Group G²: halogen, lower alkyl, —OR⁰, —CO₂R⁰ and —C(O)-aryl.

Preferably, a group selected from the following group G³ may be cited as the acceptable substituent group of the “aryl” which may be substituted in R^(a); the “aryl” which may be substituted in R^(b); the “aryl” which may be substituted in R^(ba); the “aryl” which may be substituted in R^(c); the “aryl” which may be substituted in R^(da); and the “aryl” which may be substituted in R^(e).

Group G³: halogen, —CN, lower alkyl, halogeno-lower alkyl, —OR⁰, —O-halogeno-lower alkyl, —CO₂R⁰ and —O-lower alkylene-CO₂R⁰.

Preferably, a group selected from the following group G⁴ may be cited as the acceptable substituent group of the “aryl” which may be substituted in R^(d).

Group G⁴: halogen, —CN, —NO², lower alkyl, halogeno-lower alkyl, —OR⁰, —O-halogeno-lower alkyl, —C(O)R⁰, —CO₂R⁰, lower alkylene-CO₂R⁰, —O-lower alkylene-CO₂R⁰, —OC(O)R⁰, —N(R⁰)₂, —S(O)₂-lower alkyl, aryl and heterocyclic group. However, the aryl and heterocyclic group in group G⁴ may be substituted with a group selected from a group Q. Group Q: halogen, lower alkyl, halogeno-lower alkyl, —OR⁰, —O-halogeno-lower alkyl, oxo and —CO₂R⁰.

Preferably, a group selected from the following group G⁵ may be cited as the acceptable substituent group of the “heterocyclic group” which may be substituted in R⁴; the “heterocyclic group” which may be substituted in R⁵; the “heterocyclic group” which may be substituted in R^(a); the “heterocyclic group which may be substituted in R^(b); the “heterocyclic group” which may be substituted in R^(p); the “heterocyclic group” which may be substituted in R^(ba); and the “heterocyclic group” which may be substituted in R^(e).

Group G⁵: halogen, lower alkyl, halogeno-lower alkyl, —OR⁰, —O-halogeno-lower alkyl, oxo, —CO₂R⁰, lower alkylene-C(O)R⁰, lower alkylene-CO₂R⁰ and —S(O)₂-lower alkyl.

Preferably, a group selected from the following group G⁶ may be cited as the acceptable substituent group of the “heterocyclic group” which may be substituted in R^(c); and the “heterocyclic group” which may be substituted in R^(da).

Group G⁶: halogen, lower alkyl, halogeno-lower alkyl, —OR⁰, —O-halogeno-lower alkyl, oxo, —CO₂R⁰, lower alkylene-C(O)₂R⁰, —S(O)₂-lower alkyl, aryl, —S-lower alkylene-aryl and heterocyclic group. In this regard, the aryl and heterocyclic group in group G⁶ may be substituted with a group selected from the aforementioned group Q.

Preferably, a group selected from the following group G⁷ may be cited as the acceptable substituent group of the “heterocyclic group” which may be substituted in R^(d).

Group G⁷: halogen, nitro, lower alkyl, halogeno-lower alkyl, —OR⁰, —O-halogeno-lower alkyl, oxo, —CO₂R⁰, lower alkylene-CO₂R⁰, —N(R⁰)₂, —S(O)₂-lower alkyl, —S(O)₂-aryl, aryl, lower alkylene-aryl, heterocyclic group, lower alkylene-heterocyclic group and —S-lower alkylene-CO₂R⁰. In this regard, the aryl and heterocyclic group in group G⁷ may be substituted with a group selected from the aforementioned group Q.

A preferred embodiment in the present invention is shown in the following.

(a) Preferred as R¹ is cyclohexyl or cyclopropylmethyl, more preferably cyclohexyl.

(b) Preferred as R² is —F.

(c) Preferred as R³ is —H, —OH or —F, more preferred is —H. (d) Preferred as R⁴ is lower alkyl or cycloalkyl, more preferably isopropyl, 3-pentyl or cyclopentyl, further preferred is isopropyl, 3-penthyl or cyclopentyl. (e) Preferred as R⁵ is —N(R⁰)C(O)-lower alkylene-CO₂R⁰, —N(R⁰)C(O)-lower alkenylene-CO₂R⁰, lower alkylene-CO₂R⁰, lower alkenylene-CO₂R⁰, —O-lower alkenylene-CO₂R⁰, —O-(lower alkylene which may be substituted with —CO₂R⁰)-aryl, —O-lower alkenylene-CO₂R⁰, —O-(lower alkenylene which may be substituted with —CO₂R⁰)-aryl or —O-lower alkenylene-tetrazolyl, more preferably —N(R⁰)C(O)-lower alkylene-CO₂R⁰, lower alkylene-CO₂R⁰, lower alkenylene-CO₂R⁰, —O-lower alkylene-CO₂R⁰, —O-(lower alkylene which may be substituted with —CO₂R⁰)-aryl or —O-lower alkenylene-CO₂R⁰, further preferably lower alkenylene-CO₂R⁰ or —O-lower alkylene-CO₂R⁰.

(f) Preferred as X is CH. (g) Preferred as A is CH.

Further, a compound consisting of a combination of the preferred groups of the above-mentioned (a) to (g) is more preferable.

Also, another preferred embodiment of the compound of the present invention represented by the general formula (I) is shown in the following.

(1) The compound described in the general formula (I), wherein X is CH. (2) The compound described in (1), wherein R³ is —H, —OH or —F. (3) The compound described in (2), wherein A is CH. (4) The compound described in (3), wherein R¹ is cyclohexyl or cyclopropylmethyl. (5) The compound described in (4), wherein R² is —F. (6) The compound described in (5), wherein R⁴ is lower alkyl or cycloalkyl. (7) The compound described in (6), wherein R⁵ is —N(R⁰)C(O)-lower alkylene-CO₂R⁰, lower alkylene-CO₂R⁰, lower alkenylene-CO₂R⁰, —O-lower alkylene-CO₂R⁰, —O-(lower alkylene which may be substituted with —CO₂R⁰)-aryl or —O-lower alkenylene-CO₂R⁰. (8) A compound described in the general formula (I), which is selected from the group consisting of

-   4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-4-oxobutanoic     acid, -   5-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-5-oxopentanoic     acid, -   (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylic     acid, -   (2S)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-phenylpropanoic     acid, -   (2E)-3-[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]acrylic     acid, -   (2S)-2-{[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-phenylpropanoic     acid, -   (2S)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}propanoic     acid, and -   (2S)-2-{[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}propanoic     acid,     or a pharmaceutically acceptable salt thereof.

Also, there is a case in which the compounds of the present invention form salts, and such salts are included in the compounds of the present invention as long as they are pharmaceutically acceptable salts. Illustrative examples thereof include acid addition salts with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, phosphoric acid and the like), or organic acids (e.g., formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid and the like), salts with inorganic bases including metals (e.g., sodium, potassium, calcium, magnesium and the like) or with organic bases (e.g., methylamine, ethylamine, ethanolamine, lysine, ornithine and the like), ammonium salts and the like.

In addition, the compounds of the present invention may have an asymmetric carbon atom in some cases depending on the kind of substituent groups, and optical isomers based on this may be present. The present invention includes all of the mixtures and isolated forms of these optical isomers. Also, tautomers are present in the compounds of the present invention in some cases, and the present invention includes separated forms of these isomers or mixtures thereof. In addition, a labeled substance, namely a compound in which at least one atom of the compound of the present invention is replaced by a radioisotope or non-radioactive isotope, is also included in the present invention.

In addition, various types of hydrate and solvate and polymorphism of the compound of the present invention or a pharmaceutically acceptable salt thereof are also included. In this connection, as a matter of course, the compounds of the present invention are not limited to the compounds described in the Examples which are described later, and all of the derivatives represented by the formula (I) and pharmaceutically acceptable salts thereof are included therein.

In this connection, all of the compounds which are converted in the living body into the compounds of the present invention represented by the aforementioned general formula (I), so-called prodrugs, are also included in the compounds of the present invention. As the groups which can form prodrugs of the compounds of the present invention, the groups described in Prog. Med., 5: 2157-2161 (1985), and the groups described in “Iyakuhin no Kaihatsu (Development of Medicines)”, vol. 7 Bunshi Sekkei (Molecular Design), pp. 163-198, published by Hirokawa Shoten in 1990, may be exemplified.

(Step A)

This step is a step in which a compound (I-a) of the present invention is produced by reducing a compound (1).

As the reduction reaction of this step, a carboxylic acid or ester reduction reaction generally used by those skilled in the art may be employed. For example, this may be carried out under cooling to heating reflux using equimolar to excess amount of a reducing agent such as lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride or the like, in a reaction inert solvent, for example aromatic hydrocarbons such as benzene, toluene, xylene, ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), acetonitrile, alcohols such as methanol, ethanol, and water. In addition, when the compound (1) is a carboxylic acid wherein R⁰ is —H, the carboxylic acid may also be reduced after converting it into a reactive derivative. As the reactive derivative of carboxylic acid, an acylimidazole obtained by reaction with 1,1′-carbonyldiimidazole (CDI), a mixed acid anhydride obtained by reaction with isobutyl chloroformate, etc., and the like may be cited.

(Step B)

This step is a step in which a compound (I-b) of the present invention is produced by oxidizing the compound (I-a) of the present invention.

In the oxidation reaction of this step, an alcohol oxidation reaction generally used by those skilled in the art may be used. For example, this may be carried out under room temperature to heating using equivalent to excess amount of manganese dioxide as an oxidizing agent, in a solvent such as the aforementioned aromatic hydrocarbons, halogenated hydrocarbons or the like.

(Step C)

This step is a step in which a compound (I-c) of the present invention is produced by subjecting the compound (I-b) of the present invention to an oxidation rearrangement reaction (Baeyer-Villiger) and then to hydrolysis.

The oxidation rearrangement reaction of this step may be carried out under room temperature to heating using equivalent to excess amount of m-chloroperbenzoic acid, peracetic acid, aqueous hydrogen peroxide or the like as the oxidizing agent, in a reaction inert solvent such as the aforementioned aromatic hydrocarbons, halogenated hydrocarbons, acetic acid, water or the like.

The hydrolysis reaction of this step may be carried out using an ester hydrolysis reaction generally used by those skilled in the art. For example, it may be carried out under cooling to heating in a reaction inert solvent such as the aforementioned aromatic hydrocarbons, ethers, halogenated hydrocarbons, alcohols, DMF, DMA, NMP, DMSO, pyridine, water or the like in the presence of mineral acid such as sulfuric acid, hydrochloric acid, hydrobromic acid or the like or organic acid such as formic acid, acetic acid or the like, or in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate or ammonia or the like.

Depending on the kind of the compounds, the compound (I-c) may be obtained in some cases by advancing to the hydrolysis at a stroke in the oxidation rearrangement reaction.

(Step D)

This step is a step in which a compound (I-d) of the present invention is produced by subjecting the compound (I-c) of the present invention to a nucleophilic substitution reaction.

The nucleophilic substitution reaction of this step may be carried out using an equivalent to excess amount of a compound (2), under room temperature to heating in a solvent such as the aforementioned aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMA, NMP, DMSO or the like, in the presence of a base such as potassium carbonate, tert-butoxy potassium, sodium hydride, triethylamine or the like.

Second Production Method

(In the formulae, R¹⁰ and R¹¹ mean —H, halogen, —CO₂R⁰ or lower alkyl or aryl which may respectively be substituted, and R²⁰ mean a residual part of the Horner-Emmons reagent (4), R²¹ mean a residual part of the phosphonium salt (5), X^(a−) mean Cl⁻, Br⁻ or the like counter anion, and R²² mean a residual part of the ylide compound (6).)

(Step E)

This step is a step in which a compound (I-e) of the present invention is produced by subjecting the compound (I-b) of the present invention to a reductive alkylation reaction.

The reductive alkylation reaction of this step may use a reductive alkylation reaction generally used by those skilled in the art. For example, the method described in “Jikken Kagaku Koza (Experimental Chemistry Course)” edited y The Chemical Society of Japan, Vol. 20 (1992) (Maruzen) or the like may be cited. It is desirable to carry out the reaction under cooling to heating reflux using the reducing agent such as sodium borohydride, sodium triacetoxy borohydride, or the like without solvent or in a reaction inert solvent such as the aforementioned halogenated hydrocarbons, aromatic hydrocarbons, ethers, alcohols, esters including ethyl acetate or the like, acetic acid or the like. Depending on the compounds, it is advantageous in some cases to carry out the reaction in the presence of organic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid or the like mineral acid, formic acid, acetic acid or the like or Lewis acid such as titanium(IV) chloride, tetraisopropyl orthotitanate or the like. In addition, it may also be carried out under room temperature to heating in an atmosphere of hydrogen under ordinary pressure to pressurization using, for example, palladium-carbon, rhodium-carbon, Raney nickel, platinum or the like as the catalyst, in a reaction inert solvent such as the aforementioned aromatic hydrocarbons, esters, ethers, halogenated hydrocarbons, DMF, DMA, NMP, acetonitrile, acetic acid or the like. Depending on the compound, it is advantageous in some case in effecting smooth progress of the reaction to allow it to react with an acid (preferably hydrochloric acid, acetic acid or the like).

(Step F)

This step is a step in which a compound (I-f) of the present invention is produced by subjecting the compound (I-b) of the present invention to the Horner-Emmons or Wittig reaction.

The Horner-Emmons or Wittig reaction of this step may use a method generally used by those skilled in the art. For example, when the Horner-Emmons reagent (4) or phosphonium salt (5) is used, the reaction may be carried out under cooling to heating using potassium carbonate, tert-butoxy potassium, sodium hydride, n-butyl n-butyl lithium or the like alkyl lithium or the like as a base, in a solvent such as the aforementioned aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMA, NMP, DMSO, acetonitrile or the like. Also, when the ylide compound (6) is used, the reaction may be carried out under cooling to heating in a solvent such as the aforementioned aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMA, NMP, DMSO, acetonitrile or the like.

(Step G)

This step is a step in which a compound (I-g) of the present invention is produced by reducing the double bond of the compound (I-f) of the present invention.

The reduction reaction of this step may use a method generally used by those skilled in the art. For example, it may also be carried out under room temperature to heating in an atmosphere of hydrogen under ordinary pressure to pressurization using palladium-carbon, Raney nickel, platinum or the like as the catalyst, in a reaction inert solvent such as the aforementioned aromatic hydrocarbons, esters, ethers, halogenated hydrocarbons, DMF, DMA, NMP, acetic acid or the like. Depending on the compound, it is advantageous in some case in effecting smooth progress of the reaction to allow it to react with an acid (preferably hydrochloric acid, acetic acid or the like).

Third Production Method

(In the formulae, L² represents a leaving group such as halogen, —O-methanesulfonyl, —O-p-toluenesulfonyl or the like. The same shall apply hereinafter.)

(Step H)

This step is a step in which a compound (I-h) of the present invention is produced by subjecting a compound (7) to a nucleophilic substitution reaction.

The nucleophilic substitution reaction of this step may be carried out using a compound (7) and compound (8) in equimolar amounts, or one of them in an excess amount, under room temperature to heating without solvent or in a solvent such as the aforementioned aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMSO, esters including ethyl acetate or the like, acetonitrile, alcohols or the like. Depending on the compounds, it is advantageous in some case to carry out in the presence of an organic base (triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine or the like is suitably used) or a metal salt base (potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, tert-butoxy potassium or the like is suitably used).

(Step I)

This step is a step in which a compound (I-i) of the present invention is produced by reducing the compound (I-h) of the present invention.

The nitro-reducing reaction of this step may use a method generally used by those skilled in the art. For example, it may also be carried out under room temperature to heating in an atmosphere of hydrogen under ordinary pressure to pressurization using palladium-carbon, Raney nickel, platinum or the like as the catalyst, in a reaction inert solvent such as the aforementioned aromatic hydrocarbons, esters, ethers, halogenated hydrocarbons, DMF, DMA, NMP, acetic acid or the like. Depending on the compound, it is advantageous in some case in effecting smooth progress of the reaction to allow it to react with an acid (preferably hydrochloric acid, acetic acid or the like).

Fourth Production Method

(Step J)

This step is a step in which a compound (I-j) of the present invention is produced by dehydrating a compound (9).

The dehydration reaction of this step may use a method which may be generally used in the amide dehydration reaction by those skilled in the art. For example, it may be carried out under room temperature to heating using diphosphorus pentoxide, phosphorus oxychloride, trifluoroacetic anhydride or the like as a dehydrating agent, without solvent or in a reaction inert solvent such as aromatic hydrocarbons, halogenated hydrocarbons, ethers or the like. However, when trifluoroacetic anhydride is used as the dehydrating agent, the 7-position amino group of quinolone is trifluoroacetylated in some cases depending on the kind of the compound, so that there is a case of requiring hydrolysis for the after-treatment. A method which is generally used in the amide hydrolysis by those skilled in the art may be employed in the hydrolysis.

(Step K)

This step is a step in which a compound (I-k) of the present invention is produced by reducing the compound (I-j) of the present invention.

The nitrile-reducing reaction of this step may also be carried out under room temperature to heating in an atmosphere of hydrogen under ordinary pressure to pressurization using palladium-carbon, Raney nickel, platinum or the like as the catalyst, in a reaction inert solvent such as the aforementioned aromatic hydrocarbons, esters, ethers, halogenated hydrocarbons, DMF, DMA, NMP, acetic acid or the like. Depending on the compound, it is advantageous in some case in effecting smooth progress of the reaction to allow it to react with an acid (preferably hydrochloric acid, acetic acid or the like).

Fifth Production Method

(In the formulae, J represents single bond or lower alkylene, and R¹² is R⁶ or R^(c). The same shall apply hereinafter.)

(Step L)

This step is a step in which a compound (I-m) of the present invention is produced by subjecting the compound (I-l) of the present invention to a nucleophilic substitution reaction or reductive alkylation reaction.

The nucleophilic substitution reaction and reductive alkylation reaction of this step may be carried out respectively in the same manner as in the step D and step E.

(Step M)

This step is a step in which a compound (I-n) of the present invention is produced by subjecting the compound (I-m) of the present invention to a nucleophilic substitution reaction or reductive alkylation reaction.

The nucleophilic substitution reaction and reductive alkylation reaction of this step may be carried out respectively in the same manner as in the step D and step E.

Sixth Production Method

(Step N)

This step is a step in which a compound (I-p) of the present invention is produced by an amidation reaction of a compound (I-o) of the present invention with a compound (10) or a reactive derivative thereof.

The amidation reaction of this step may use an amidation which may be generally used by those skilled in the art. Particularly, a method which uses condensing agent such as carbonyldiimidazole (CDI), 1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl), dicyclohexylcarbodiimide, diphenylphosphoryl azide, diethylphosphoryl cyanide or the like, a method which is carried out by way of a mixed acid anhydride using isobutyl chloroformate, ethyl chloroformate and the like, and a method which is carried out by way of an acid halide using thionyl chloride, phosphorus oxychloride or the like are suitable. The reaction conditions may be optionally selected depending on the reactive derivative and condensing agent to be used, and this is generally carried out under cooling, under cooling to room temperature, or under room temperature to heating in a reaction inert solvent such as halogenated hydrocarbons, aromatic hydrocarbons, ethers, DMF, DMSO or the like. Depending on the reaction, it is advantageous in some case to carry out in the presence of an organic base (triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine or the like is suitably used) or a metal salt base (potassium carbonate, cesium carbonate or the like is suitably used).

Seventh Production Method

(In the formulae, L³ represents a leaving group such as —O-lower alkyl, —O-p-nitrophenyl or the like.)

(Step O)

This step is a step in which a compound (I-r) of the present invention is produced by urea formation of a compound (I-q) of the present invention.

The urea formation reaction may be carried out under room temperature to heating using equivalent amounts of the compound (I-q) and a compound (11), or one f them in an excess amount, in a reaction inert solvent such as aromatic hydrocarbons, halogenated hydrocarbons, ethers, DMF, DMSO or the like. Depending on the reaction, it is advantageous in some case to carry out in the presence of an organic base (triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene or the like is suitably used) or a metal salt base (potassium carbonate, cesium carbonate or the like is suitably used).

In addition, several compounds represented by the formula (I) may also be produced from the compounds obtained in the above manner by optionally combining steps such as conventionally known alkylation, acylation, substitution reaction, oxidation, reduction, hydrolysis and the like, which may be generally employed by those skilled in the art. Particularly, the compounds (I-a), (I-b), (I-c), (I-h), (I-i) and (I-j) of the present invention are also useful as the synthesis intermediates of the compounds of the present invention.

(Synthesis of Starting Compounds)

The starting compounds to be used in the production of the compound (I) of the present invention may be synthesized using the following methods, conventionally known methods or modified methods thereof

(Starting Material Synthesis 1)

The compound (1-a) may be produced using the method described in the Patent Reference 7 or a modified method thereof

(Step P)

This step is a step in which the compound (9) is produced by the amidation of the compound (1-a).

Regarding the amidation reaction of this step, it may be produced for example by the method described in the step N.

(Starting Material Synthesis 2)

(Step Q)

This step is a step in which a compound (14) is produced by a condensation reaction of a compound (12) with an orthoformic ester and subsequent addition elimination reaction by a compound (13).

The condensation reaction of this step by an orthoformic ester may be carried out under room temperature to heating by using a reagent which captures alcohols generated from the orthoformic ester as a solvent such as acetic anhydride, or by using a reagent which captures alcohols generated from the orthoformic ester in a reaction inert solvent such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO, esters, acetonitrile or the like.

The addition elimination reaction after the above-mentioned condensation reaction may be carried out under cooling, room temperature or heating in a reaction inert solvent such as alcohols, halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO or the like. In this connection, the reaction may also be carried out using excess amount of the compound (13). Depending on the compounds, it is advantageous in some case to carry out in the presence of an organic base (triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine or the like is suitably used) or a metal salt base (potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, tert-butoxy potassium or the like is suitably used).

(Step R)

This step is a step in which a compound (7) is produced by an intramolecular cyclization reaction of the amino group of the compound (14).

The intramolecular cyclization reaction of this step may be carried out under cooling, room temperature or heating in a reaction inert solvent such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, DMF, DMSO or the like. Depending on the compounds, it is advantageous in some case to carry out in the presence of an organic base (triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]-7-undecene or the like is suitably used) or a metal salt base (potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, tert-butoxy potassium or the like is suitably used).

The compound of the present invention produced in this manner is isolated and purified directly as free or as a salt thereof by applying a salt formation treatment in the usual way. The isolation and purification are carried out by employing general chemical operations such as extraction, concentration, evaporation, crystallization, filtration, recrystallization, various types of chromatography and the like.

Various types of isomers may be isolated in the usual way making use of the difference in the physicochemical properties between isomers. For example, a racemic mixture may be converted into an optically pure isomer by a general racemic resolution method including for example converting to diastereomer salts with optically active acid such as a tartaric acid and subsequent optical resolution. Also, a diastereomer mixture may be separated, for example, by a fractional recrystallization or various types of chromatography. In addition, an optically active compound may also be produced using an appropriate optically active compound as the starting material.

The pharmaceutical composition which contains one or more of the compounds of the present invention or pharmaceutically acceptable salts thereof as the active ingredient is prepared using carriers and fillers and other additive agents generally used in preparing pharmaceuticals.

Its administration may be in the form of either oral administration by tablets, pills, capsules, granules, powders, solutions and the like, or parenteral administration by intravenous, intramuscular or the like injections, suppositories, percutaneous preparations, transnasal preparations, inhalations and the like. Its dose is optionally decided by taking into consideration symptom, age, sex and the like of the object to be treated in response to each case, but in the case of oral administration, it is generally approximately from 0.001 mg/kg to 100 mg/kg per day per adult, and this is administered in one portion or by dividing into 2 to 4 portions. Also, in the case of intravenous administration, it is administered within the range of from 0.0001 mg/kg to 10 mg/kg per adult, once or two or more times per day. In addition, in the case of transnasal administration, it is administered within the range of from 0.0001 mg/kg to 10 mg/kg per adult, once or two or more times per day.

As the solid composition for oral administration by the present invention, tablets, powders, granules and the like are used. In such a solid composition, one or more active substances are mixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, aluminum magnesium silicate or the like. In accordance with the usual way, the composition may contain additive agents other than the inert diluent, such as lubricant (e.g., magnesium stearate or the like), disintegrating agent (e.g., calcium cellulose glycolate or the like), a stabilizing agent, solubilizing agent and the like. When necessary, tablets or pills may be coated with a sugar coating or film of a gastric or enteric substance, such as of sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate or the like.

The liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contains a generally used inert diluent such as purified water or ethanol EtOH). In addition to the inert diluent, this composition may contain a moistening agent, a suspending agent and the like auxiliary agents, as well as sweeteners, flavors, aromatics and antiseptics.

As the injections for parenteral administration, aseptic aqueous or non-aqueous solutions, suspensions and emulsions are included. As the aqueous solutions and suspensions, for example, distilled water for injection and physiological saline are included. As the non-aqueous solutions and suspensions, for example, there are propylene glycol, polyethylene glycol, olive oil or the like plant oil, EtOH or the like alcohols, polysorbate 80 and the like. Such a composition may further contain auxiliary agents such as an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, a solubilizing agent or the like. These are sterilized for example by filtration through a bacteria retaining filter, blending of a germicide or irradiation. These may also be used by producing sterile solid compositions and dissolving them in sterile water or a sterile solvent for injection prior to their use.

Pharmacological activities of the compounds of the present invention were verified by the following tests.

Test Method (1) Human Platelet Aggregation Inhibition Activity Measuring Test

A blood sample was collected from a healthy volunteers (male adult) using a syringe containing 1/10th volume of 3.8% sodium citrate solution and centrifuged at 160×g for 10 minutes, thereby separating platelet rich plasma (PRP) of the supernatant. Remaining blood after the collection of PRP was centrifuged at 1,800×g for 10 minutes to separate platelet poor plasma (PPP). The number of platelets in the PRP was measured by an automatic blood cell counter (MEK-6258, Nihon Kohden Corp.), and then the number of platelets was adjusted to 3×10⁸/ml by adding PPP to PRP and used in the following test. The ADP as an inducer of platelet aggregation was purchased from MC Medical. Platelet aggregation was measured using an aggregometer (MCM Hematracer 212; MC Medical). That is, 80 μl of PRP of 3×10⁸ platelets/ml and 10 μl of a test compound solution or a solvent (10% DMSO or 10% DMSO-9% hydroxypropyl-β-cyclodextrin-4.5% d-mannitol) were incubated at 37° C. for 1 minute, and then 10 μl of ADP (50 μM) was added thereto to induce platelet aggregation, and changes in transmitted light were recorded for 5 minutes. The inhibition ratio was calculated using the area under platelet aggregation curve as an index. The results at 10 μM (final concentration) of compounds of the present invention are shown in Table 1.

In this connection, REx represents reference example number, and Ex Example compound number. In addition, Reference Examples 1 and 2 are the Example compounds described in the aforementioned Patent Reference 7, and were produced in accordance with the method described in said patent reference.

Reference Example 1 Example 467 of Patent Reference 7 4-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)butanoic Acid Reference Example 2 Example 6 of Patent Reference 7 ({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)acetic Acid

TABLE 1 Compound to be tested Inhibition % REx 1 64 REx 2 79 Ex 2 93 Ex 76 94 Ex 80 92 Ex 82 89 Ex 87 92 Ex 114 85 Ex 125 91 Ex 146 83 Ex 202 94 Ex 261 97 Ex 271 91 Ex 297 89 Ex 321 93 Ex 354 85 Ex 380 89 Ex 407 84 Test Method (2) Substitution Test for the Binding of Human P2Y12 with 2-methylthio-ADP (2-MeS-ADP)

A C6-15 cell was inoculated into a 10 cm petri dish to a density of to 1×10⁶ cells using DMEM medium and cultured for 1 day, and then 8 μg of a plasmid pEF-BOS-dfhr-human P2Y12 and 0.8 μg of pEF-BOS-neo (Nucleic Acid Res., 18, 5322, 1990) were gene-transferred using a transfection reagent (LipofectAMINE 2000; mfd. by GIBCO BRL).

24 hours after the aforementioned gene transfer operation, the gene-transferred cells were recovered, suspended in DMEM medium supplemented with 0.6 mg/ml of G 418 (mfd. by GIBCO BRL) and then serially diluted and inoculated again in a 10 cm petri dish. The colonies appeared after 2 weeks were individually obtained and used in the following test as P2Y12 protein expression C₆₋₁₅ cells (WO 02/36631, Mol. Pharmacol., 60, 432, 2001).

After culturing the P2Y12 protein expression C₆₋₁₅ cells, the cells were recovered. The cells were washed with PBS, and then suspended in 20 mM Tris-HCl (pH 7.4) containing 5 mmol/l of EDTA and a protease inhibitor cocktail set Complete™ (mfd. by Boehringer-Mannheim) and homogenized using Polytron. After carrying out ultracentrifugation, the precipitate was suspended in 50 mM Tris-HCl (pH 7.4) containing 1 mM EDTA, 100 mM NaCl and Complete™, and this was used as a membrane fraction.

A 100 μl portion of the P2Y12 protein expression C6-15 cell membrane fraction (100 μg/ml) obtained in the above was mixed with 1.5 μl of a test compound solution and 50 μl of 0.75 nM [³H]-2-MeS-ADP (80 Ci/mmol, mfd. by Amersham Pharmacia Biotech) or 0.75 nM [³³P]-2-MeS-ADP (2100 Ci/mmol, mfd. by Perkin Elmer), incubated at room temperature for 1 hour in 50 mM Tris-HCl (pH 7.4) containing 100 mM NaCl and 50 mM MgCl₂, and then recovered on a glass filter using a cell harvester. A microscintillator was added to the glass filter, and the radioactivity was measured using a liquid scintillation counter. Those to which the solvent alone was added and 1.5 μl of 250 μM ADP was added in the aforementioned test at the same time were regarded as total binding and nonspecific binding, and their radioactivity was measured. By regarding the total binding and nonspecific binding as inhibition ratio 0% and 100% respectively, inhibition ratio (%) of each compound to be tested was calculated. The results at 30 nM (final concentration) of compounds of the present invention are shown in Table 2.

TABLE 2 Compound to be tested Inhibition % REx 1 76 REx 2 86 Ex 2 89 Ex 80 89 Ex 82 65 Ex 87 87 Ex 114 92 Ex 125 83 Ex 146 92 Ex 196 86 Ex 202 82 Ex 261 67 Ex 271 80 Ex 321 73 Ex 324 92 Ex 380 96 Ex 407 72 Ex 488 35

Test Method (3) Rat Platelet Aggregation Inhibition Test and Measurement of Test Compound Concentration in Plasma

By adding sodium hydroxide aqueous solution to the compound of the present invention, 0.5% methyl cellulose aqueous solution or suspension was prepared. The thus prepared liquid was orally administered using a sonde to a male SD rat (5 to 7 weeks of age) of after 12 hours or more of fasting. After 2 hours of the compound administration, blood was collected using a syringe containing 1/10th volume of 3.8% sodium citrate solution. In the same manner as in Test method (1), PPP and PRP of 3×10⁸ platelets/ml were prepared. A 90 μl portion of the PRP of 3×10⁸ platelets/ml was incubated at 37° C. for 1 minute, and then 10 μl of ADP (50 μM) was added thereto to induce platelet aggregation, and changes in transmitted light were recorded for 5 minutes. The inhibition ratio was calculated using the area under platelet aggregation curve as an index.

The concentration in plasma was measured using the PPP prepared in the above. In order to prepare a standard curve, a PPP of an SD rat to which the compound was not administered was also separated, and those in which the compound of the present invention was serially diluted with this PPP (from 30 μM to 0.0003 μM in final concentration: optionally selects in response to each compound) were also prepared. A 100 μl portion of the PPP of a rat to which the compound of the present invention was administered and the PPP containing the diluted compound of the present invention was mixed with the same volume of distilled water, and 5% trichloroacetic acid was further added thereto and mixed. After allowing to stand on ice for 10 minutes, a supernatant was recovered by a centrifugation operation. The supernatant was neutralized by adding 3 μl of 2 M Tris base thereto and mixing. A 150 μl portion of the P2Y12 protein expression C6-15 cell membrane fraction (200 μg/ml) was mixed with 50 μl of this trichloroacetic acid-treated PPP (depending on the compound, PPP diluted with 50 mM Tris-HCl (pH 7.4) containing 100 mM NaCl and 50 mM MgCl₂ was used). Further, 50 μl of 0.75 nM [³H]-2-MeS-ADP (80 Ci/mmol, mfd. by Amersham Pharmacia Biotech) or 0.75 nM [³³P]-2-MeS-ADP (2100 Ci/mmol, mfd. by Perkin Elmer) was added thereto and incubated at room temperature for 1 hour in 50 mM Tris-HCl (pH 7.4) containing 100 mM NaCl and 50 mM MgCl₂, followed by recovery on a glass filter using a cell harvester. A microscintillator was added to the glass filter, and the radioactivity was measured using a liquid scintillation counter. Using the binding inhibition curve calculated from the measured results derived from PPP containing the serially diluted compound of the present invention as a standard curve, concentration of the compound of the present invention in PPP was converted from the measured results derived from the rat to which the compound of the present invention was administered.

The results are shown in Table 3. As a result of the evaluation by the above-mentioned method, it was revealed that the compound of the present invention shows good platelet aggregation inhibition activity by oral administration and also shows good pharmacokinetics.

TABLE 3 Dose Compound to be tested mg/kg Inhibition % REx 1 30 11 REx 2 30 −7 Ex 82 10 75 Ex 87 10 72 Ex 114 3 66 Ex 125 30 89 Ex 146 30 72 Ex 271 30 89 Ex 297 30 48 Ex 380 30 74 Ex 407 30 54

EXAMPLES

The present invention is illustratively described based on examples, but the present invention is not restricted by these examples. In this connection, since novel substances are included in the starting compounds to be used in the Examples, production methods from such starting compounds are described as production examples.

In this connection, symbols in the production examples and Examples represent the following meanings (the same shall apply hereinafter).

Rf: production example number, Ex: Example number, No: compound number, Data: physical data (Sal: salt (No description means free form, and the numeral before the acid component shows compositional ratio. For example, when 2HCl is described, it shows that the compound is dihydrochloride. Oxa: oxalate, TFA: trifluoroacetate)), NMR: δ (ppm) of characteristic peak in ¹H-NMR, EI: EI-MS (M⁺ unless otherwise noted), FAB: FAB-MS (Pos) (M⁺+1 unless otherwise noted), ESI: ESI-MS (Pos) (M⁺+1 unless otherwise noted), ACPI: ACPI-MS (Pos) (M⁺+1 unless otherwise noted), ESI(Neg): ESI-MS (Neg) (M⁻−1 unless otherwise noted), FAB(Neg): FAB-MS (Neg) (M⁻⁻1 unless otherwise noted), Me: methyl, Et: ethyl, nPr, normal propyl, iPr: isopropyl, cPr: cyclopropyl, nBu: normal butyl, iBu: isobutyl, tBu: tert-butyl, cBu: cyclobutyl, cPen: cyclopentyl; cHex: cyclohexyl, Ph: phenyl, Bn: benzyl, Boc: tert-butoxycarbonyl, Ac: acetyl, Bz: benzoyl, TBDMS: tert-butyldimethylsilyl. Syn: production method (The numeral shows that, similar to the Example compound having the number as its Example number, it was produced using the corresponding starting material. When Rf is added before the numeral, it shows that, similar to the production example compound having the number as its production example number, it was produced using the corresponding starting material. When two or more numerals are written, it shows that it was produced by carrying out corresponding production methods starting from the first numeral.), RSyn: production method (The numeral shows that, similar to the production example compound having the number as its production example number, it was produced using the corresponding starting material. When E is added before the numeral, it shows that, similar to the Example compound having the number as its Example number, it was produced using the corresponding starting material.).

Production Example 1

2.6 g of 1,1′-carbonyldiimidazole was added to a 30 ml DMF suspension of 4.0 g 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, followed by stirring at 100° C. for 13.5 hours. 10 ml of 28% aqueous ammonia was added thereto under ice-cooling, followed by stirring under ice-cooling for 75 minutes and at room temperature for 5 hours. After evaporation of the solvent under a reduced pressure, ethanol was added, and heating under reflux was carried out. After cooling to room temperature, the insoluble materials were collected by filtration and dried to obtain 3.7 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide.

Production Example 2

0.87 ml of triethylamine and 0.4 ml of isobutyl chloroformate were added to a 20 ml of dichloromethane solution of 1.0 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid at 0° C., followed by stirring at 0° C. for 30 minutes. Then, 315 mg of N,O-dimethylhydroxylamine hydrochloride was added thereto, followed by stirring at room temperature for 1 hour. Chloroform and aqueous saturated ammonium chloride were added to the reaction mixture, the layers were separated, and the organic layer was washed with aqueous saturated so iumchloride. After drying over anhydrous sodium sulfate and subsequent filtration, the solvent was evaporated under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 950 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-N-methoxy-N-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide was obtained.

Production Example 3

5 g of 2-nitro-1-(2,4,5-trifluorophenyl)ethanone was dissolved in 100 ml of acetic anhydride, and 4.0 ml of triethyl orthoformate was added thereto at room temperature, followed by stirring at 130° C. for 3 hours and concentration under a reduced pressure. The resulting residue was dissolved in 100 ml of dichloromethane, and a 50 ml dichloromethane solution of 2.5 ml of cyclopentylamine was added under ice-cooling, followed by stirring at room temperature for 3 hours. Then, water was added, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then concentrated under a reduced pressure. The resulting residue was dissolved in 80 ml of 1,4-dioxane, and a 20 ml dioxane solution of 3.6 ml 1,8-diazabicyclo[5.4.0]-7-undecene was added at room temperature, followed by stirring at room temperature for 3 hours. By pouring the resulting reaction mixture into ice-cooled water and collecting the insoluble materials by filtration, 1.8 g of 1-cyclopentyl-6,7-difluoro-3-nitroquinoline-4(1H)-one was obtained.

Production Example 4

Under ice-cooling, 11.5 g of sodium triacetoxyborohydride was added in small portions to a solution of 4.0 g of 3,4,5-trifluoroaniline and 3.6 ml cyclopentanone in 150 ml dichloroethane and 3.1 ml acetic acid, and, after rising to room temperature, stirred for 3.5 hours. Aqueous saturated sodium hydrogen carbonate was added thereto, followed by extraction with chloroform and subsequent drying over anhydrous sodium sulfate. After filtration, the solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 5.4 g of N-cyclopentyl-3,4,5-trifluoroaniline.

Production Example 5

3.2 ml of diethyl(ethoxymethylene)malonate was added to 3.3 g of N-cyclopentyl-3,4,5-trifluoroaniline, followed by stirring at 130° C. for 4 hours. By purifying by silica gel column chromatography, 2.2 g of diethyl {[cyclopentyl(3,4,5-trifluorophenyl)amino]methylene}malonate was obtained.

Production Example 6

5.7 g of polyphosphoric acid was added to 2.2 g of diethyl {[cyclopentyl(3,4,5-trifluorophenyl)amino]methylene}malonate, followed by stirring at 140° C. for 40 minutes. The reaction mixture was poured into ice water, and the insoluble materials were collected by filtration. This was dissolved in chloroform, washed with water and aqueous saturated sodium chloride and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated to obtain 1.4 g of ethyl 1-cyclopentyl-5,6,7-trifluoro-4-oxo-1,4-dihydro quinoline-3-carboxylate.

Production Example 7

42% hydrofluoboric acid was added to 1.1 g of ethyl 1-cyclopentyl-5,6,7-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, followed by heating at 90° C. for 20 hours. Water was added to the reaction mixture, and the thus formed insoluble materials were collected by filtration and dried to obtain 1.4 g of a boron compound. To 1.4 g of this boron compound were added 15 ml of DMSO and 0.97 ml of cyclohexylamine, followed by stirring at room temperature for 30 minutes. Water was added to the reaction mixture, and the insoluble materials were collected by filtration. After drying, 30 ml of ethanol and 15 ml of aqueous 1 M sodium hydroxide solution were added thereto, followed by stirring at 80° C. for 1.5 hours. After completion of the reaction, the insoluble materials were removed by filtration, water and diethyl ether were added to the filtrate to carry out separation of layers, and 1 M hydrochloric acid was added to the aqueous layer. The precipitate formed was collected by filtration and dried to obtain 1.0 g of 7-(cyclohexylamino)-1-cyclopentyl-5,6-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.

Production Example 8

Under ice-cooling, 3.2 ml of n-butyl lithium (1.60 M hexane solution) was added to a 2.4 ml THF solution of 0.58 ml benzyl alcohol, followed by stirring for 1 hour. The solvent was evaporated under a reduced pressure, followed by the addition of 8.0 ml of toluene for suspension. The suspension prepared was added to a toluene suspension of 400 mg of 7-(cyclohexylamino)-1-cyclopentyl-5,6-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which was prepared in a separate container, followed by stirring at room temperature for 6 hours. Then, 1 M hydrochloric acid was added to the reaction mixture, followed by extraction with chloroform and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent filtration, the solvent was evaporated under a reduced pressure. By recrystallizing the resulting residue using ethyl acetate, 400 mg of 5-(benzyloxy)-7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was obtained.

Production Example 9

900 mg of ethyl 1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate was dissolved in 6.4 ml of acetic acid, and 0.8 ml of 6 M hydrochloric acid was added, followed by overnight stirring at 120° C. The resulting reaction mixture was cooled to room temperature, and the insoluble materials were collected by filtration and washed with water to obtain 710 mg of 1-cyclopentyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.

Production Example 10

1.02 g of 1-cyclobutylethylamine hydrochloride and 1.05 ml of triethylamine were added under ice-cooling to a 15 ml THF solution of 2.0 g of ethyl 2-(2-chloro-4,5-difluorobenzoyl)-3-ethoxyacrylate, followed by overnight stirring at room temperature. Water was added to the resulting reaction mixture, followed by extraction with ether and washing with water and aqueous saturated sodium chloride. After drying over anhydrous magnesium sulfate, concentration under a reduced pressure was carried out. 315 mg of 55% sodium hydride was added under ice-cooling to a 30 ml dioxane solution of the resulting residue, followed by overnight stirring at 80° C. The reaction mixture was poured into 1 M hydrochloric acid, followed by extraction with chloroform and washing with water and aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent concentration under a reduced pressure, the resulting residue was purified by silica gel column chromatography to obtain 1.13 g of ethyl 1-(1-cyclobutylethyl)-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate.

In the same manner as in the Production Examples 1 to 10, Production Example compounds 11 to 27 shown in Tables 4 to 9 were produced using corresponding starting materials, respectively. Structures and physicochemical date of Production Example compounds are shown in Tables 4 to 9.

Example 1

250 mg of 3-amino-7-(cyclohexylamino)-1-cyclopentyl-6-fluoroquinoline-4(1H)-one and 127 mg of 4-ethoxy-4-oxobutanoic acid were dissolved in 20 ml of DMF, and 170 mg of N-[3-(dimethylamino)propyl]-N′-ethylcarbodiimide hydrochloride and 160 mg of 1-hydroxybenzotriazole were added, followed by overnight stirring at room temperature. By adding water to the reaction mixture and collecting the insoluble materials by filtration, 220 mg of ethyl 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-4-oxobutanoate was obtained.

Example 2

200 mg of ethyl 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-4-oxobutanoate was dissolved in 2.0 ml of THF and 2.0 ml of ethanol, and 1.3 ml of aqueous 1M sodium hydroxide solution was added, followed by stirring at room temperature for 4 hours. After adding 1 M hydrochloric acid and water thereto, the insoluble materials were collected by filtration to obtain 180 mg of 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-4-oxobutanoic acid.

Example 3

200 mg of diethyl {(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]vinyl}phosphonate was dissolved in 2.0 ml of chloroform, and 0.4 ml of bromotrimethylsilane was added, followed by overnight stirring at room temperature. Ethanol was added to the reaction mixture, followed by concentration under a reduced pressure. Ethyl acetate was added to the resulting residue, and the insoluble materials were collected by filtration to obtain 120 mg of {(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]vinyl}phosphonic acid hydrobromide.

Example 4

169 mg of sodium triacetoxyborohydride was added to a mixed solution 10 ml of 1,2-dichloroethane and 0.05 ml of acetic acid of 142 mg 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde and 66 mg of 4-aminophenol, followed by stirring for 24 hours. Aqueous saturated sodium hydrogen carbonate was added thereto, followed by extraction with chloroform. After drying over anhydrous sodium sulfate and subsequent filtration, concentration under a reduced pressure was carried out. The resulting residue was purified by silica gel column chromatography and then crystallized from ethyl acetate to obtain 46 mg of [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-{[(4-hydroxyphenyl)amino]methyl}quinolin-4(1H)-one.

Example 5

250 mg of 3-(aminomethyl)-7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoroquinolin-4(1H)-one hydrochloride was dissolved in 25 ml of THF, and 0.11 ml of diethyl (2-oxopropyl)phosphonate and 123 mg of sodium triacetoxyborohydride, 0.16 ml of triethylamine and 1.25 ml of acetic acid were added in that order, followed by overnight stirring at room temperature. Water was added, and the insoluble materials were collected by filtration and then purified by silica gel column chromatography to obtain 135 mg of diethyl [2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)propyl]phosphonate.

Example 6

170 mg of ethyl 4-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)butanoate was dissolved in 2.0 ml of pyridine, and 0.040 ml of acetic anhydride was added, followed by overnight stirring at room temperature. After concentrating the reaction mixture under a reduced pressure, water was added to the resulting residue, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered and concentrated under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 165 mg of ethyl 4-(acetyl {[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)butanoate was obtained.

Example 7

180 mg of 4-nitrophenyl chloroformate was dissolved in 3.0 ml of dichloromethane, and 140 mg of ethyl 3-aminopropanoate hydrochloride and 0.15 ml of pyridine were added, followed by overnight stirring at room temperature. Water was added to the reaction mixture, followed by extraction with chloroform. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and then concentrated under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 180 mg of ethyl 3-{[(4-nitrophenoxy)carbonyl]amino}propanoate was obtained. 180 mg of ethyl 3-{[(4-nitrophenoxy)carbonyl]amino}propanoate was dissolved in 2.0 ml of dichloromethane, and 220 mg of 3-amino-7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoroquinolin-4(1H)-one and 0.15 ml of pyridine were added, followed by overnight stirring at room temperature. Water was added, followed by extraction with chloroform. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and then filtered and concentrated under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 120 mg of ethyl 3-[({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}carbonyl)amino]propanoate was obtained.

Example 8

287 mg of ethyl [(5-chloro-2-thienyl)sulfonyl]carbamate was dissolved in 5.0 ml of toluene, and 250 mg of 3-amino-7-(cyclohexylamino)-6-fluoro-1-isopropylquinolin-4(1H)-one was added, followed by overnight stirring at 110° C. The reaction mixture was cooled to room temperature and concentrated under a reduced pressure. Then, ethyl acetate was added and the insoluble materials were collected by filtration, thereby obtaining 280 mg of 5-chloro-N-({[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]amino}carbonyl)thiophene-2-sulfonamide.

Example 9

224 mg of 2-amino-N-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acetamide hydrochloride was dissolved in 5.0 ml of DMF, and 228 mg of potassium carbonate and 0.18 ml of ethyl bromoacetate were added, followed by overnight stirring at 60° C. The reaction mixture was cooled to room temperature, water was added, and the insoluble materials were collected by filtration to obtain 35 mg of diethyl 2,2′-[(2-{[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-2-oxoethyl)imino]diacetate.

Example 10

150 mg of ethyl {[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}acetate was dissolved in 3.0 ml of THF, and 0.060 ml of triethylamine and 0.060 ml of ethyl 5-chloro-5-oxopentanoate were added, followed by overnight stirring at room temperature. Water was added to the reaction mixture, followed by extraction with chloroform. The resulting organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and then concentrated under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 199 mg of ethyl 5-[[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](2-ethoxy-2-oxoethyl)amino]-5-oxopentanoate was obtained.

Example 11

200 mg of ethyl (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylate was dissolved in 4.0 ml of ethanol, and 50 mg of palladium-carbon was added, followed by overnight stirring at room temperature in an atmosphere of hydrogen. The reaction mixture was filtered using celite and concentrated under a reduced pressure to obtain 200 mg of ethyl (3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]propanoate.

Example 12

213 μl of diisopropyl azodicarboxylate was added to a 5.0 ml dichloromethane solution of 263 mg of benzyl (2R)-2-hydroxy-3-phenylpropanoate and 270 mg of triphenylphosphine at 0° C., followed by stirring for 15 minutes. Then, 177 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(hydroxymethyl)quinolin-4(1H)-one was added thereto, followed by stirring at room temperature for 4 hours. Water was added to the reaction mixture, followed by extraction with EtOAc and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent evaporation under a reduced pressure, the residue was purified by silica gel column chromatography to obtain 160 mg of benzyl (2S)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-phenylpropanoate.

Example 13

690 mg of potassium carbonate and 363 mg of 4-fluorobenzonitrile were added to a 10 ml DMF solution of 344 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-hydroxyquinolin-4(1H)-one, followed by overnight stirring at 80° C. After completion of the reaction and subsequent cooling to room temperature, aqueous saturated ammonium chloride was added to the reaction mixture, followed by extraction with ethyl acetate. After drying over anhydrous sodium sulfate and subsequent evaporation under a reduced pressure, the residue was purified by silica gel column chromatography to obtain 100 mg of 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}benzonitrile.

Example 14

5.0 ml of ethanol and 1.5 ml of aqueous 6 M sodium hydroxide solution were added to 93 mg of 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}benzonitrile, followed by heating under reflux for 2 days. After cooling, the reaction system was neutralized with 1 M hydrochloric acid. Water was added and the solid precipitated was collected by filtration. By crystallizing the resulting solid from ethyl acetate-hexane, 65 mg of 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}benzoic acid was obtained.

Example 15

840 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was dissolved in 40 ml of chloroform, and 0.47 ml of trimethylsilyl cyanide and 0.05 ml of triethylamine was added under ice-cooling, followed by stirring at room temperature for 5.5 hours. After stirring at room temperature for 1.5 hours after further adding 0.06 ml of trimethylsilyl cyanide, 0.06 ml of trimethylsilyl cyanide was further added thereto, followed by stirring at room temperature for 2 days. The resulting precipitate was filtered and washed with chloroform to obtain a solid. The resulting solid was dissolved in 13 ml of concentrated hydrochloric acid, followed by stirring at 100° C. for 2.5 hours. After cooling to room temperature, water was added, followed by extraction with chloroform, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain crude product of [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](hydroxy)acetic acid. The resulting crude product was washed with water:methanol (1:2) and ethyl acetate. Ethyl acetate and aqueous saturated sodium hydrogen carbonate were added to the resulting solid to carry out layer separation operation. 1 M hydrochloric acid was added to the aqueous layer, followed by extraction with ethyl acetate and concentration under a reduced pressure. A mixed solvent of THF and water was added to the resulting residue and the insoluble materials were collected by filtration to obtain 149 mg of [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](hydroxy)acetic acid.

Example 16

52 mg of [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](hydroxy)acetic acid was dissolved in 10 ml of methanol, and 0.4 ml of concentrated sulfuric acid was added, followed by stirring at room temperature for 1 hour. Aqueous saturated sodium hydrogen carbonate was added to the reaction mixture, followed by extraction with ethyl acetate, washing with aqueous saturated sodium chloride and concentration under a reduced pressure. The resulting residue was recrystallized from aqueous methanol to obtain 53 mg of methyl [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](hydroxy)acetate.

Example 17

146 mg of methyl [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](hydroxy)acetate was dissolved in 10 ml of THF, and 46 mg of 60% sodium hydride was added under ice-cooling, followed by stirring at room temperature for 30 minutes. Then, 58 μl of ethyl bromoacetate was added to the reaction mixture, followed by stirring at room temperature for 5 hours. 46 mg of 60% sodium hydride and 10 ml of THF were further added under ice-cooling, followed by stirring at room temperature for 2 hours. Then, 58 μl of ethyl bromoacetate was added thereto, followed by stirring at room temperature for 17 hours. Aqueous saturated sodium hydrogen carbonate was added to the reaction mixture, followed by extraction with ethyl acetate. Then, the organic layer was washed with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, concentration was carried out under a reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain 66 mg of methyl [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](2-ethoxy-2-oxoethoxy)acetate.

Example 18

13 g of diethyl {(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]vinyl}phosphonate was dissolved in 150 ml of chloroform, and 27.2 ml of bromotrimethylsilane was added, followed by overnight stirring at room temperature. Ethanol was added to the reaction mixture, followed by concentration under a reduced pressure. Aqueous 1 M sodium hydroxide solution and ether were added to the resulting residue to carry out layer separation operation. Concentrated hydrochloric acid was added to the aqueous layer, followed by stirring at room temperature for 2 hours. Then, the insoluble materials were collected by filtration and washed with water to obtain 10.32 g of {(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]vinyl}phosphonic acid.

Example 19

428 mg of (methoxymethyl)triphenylphosphonium chloride was dissolved in 5 ml of THF, and 1.2 ml of 1.6 M n-butyl lithium hexane solution was added under ice-cooling in an atmosphere of argon, followed by stirring at the same temperature for 30 minute. A 5 ml THF solution of 178 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was added under ice-cooling thereto, followed by stirring at the same temperature for 15 minutes and then stirring at room temperature for 3 hours. The reaction mixture was poured into ice water, followed by extraction with ethyl acetate, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. The resulting residue was dissolved in 10 ml of dioxane, and 5 ml of a 4 M hydrogen chloride dioxane solution was added, followed by stirring at room temperature for 2 hours. The reaction mixture was poured into an ice-cooled aqueous saturated sodium hydrogen carbonate, followed by extraction with ethyl acetate, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 239 mg of crude product of [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acetaldehyde was obtained. The resulting crude product was dissolved in 10 ml of ethanol, and 75 mg of sodium borohydride was added, followed by stirring at room temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. The resulting residue chain was purified by silica gel column chromatography and crystallized from ethyl acetate to obtain 18 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(2-hydroxyethyl)quinolin-4(1H)-one.

Example 20

856 mg of (methoxymethyl)triphenylphosphonium chloride was dissolved in 10 ml of THF, and 1.8 ml of a 1.6 M n-butyl lithium hexane solution was added under ice-cooling in an atmosphere of argon, followed by stirring at the same temperature for 30 minute. A 10 ml THF solution of 356 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was added under ice-cooling thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was poured into ice water, followed by extraction with ethyl acetate, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. The resulting residue was purified by column chromatography to obtain 552 mg crude product of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-[2-methoxyvinyl]quinolin-4(1H)-one. 159 mg of the resulting crude product was dissolved in 14 ml of dioxane, and 7 ml of a 4 M hydrogen chloride dioxane solution was added, followed by stirring at room temperature for 0.5 hour. The reaction mixture was concentrated under a reduced pressure, and the resulting residue was dissolved in 6 ml of 2-methyl-2-propanol, 1 ml of acetonitrile and 2 ml of water. Then, 0.26 ml of 2-methyl-2-butene, 78 mg of sodium dihydrogenphosphate dihydrate and 228 mg of a 79% sodium chlorite aqueous solution were added under ice-cooling, followed by stirring at room temperature for 14 hours. Water was added to the reaction mixture, followed by extraction with chloroform, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. The resulting residue was purified by silica gel column chromatography and crystallized from ethyl acetate to obtain 5 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acetic acid.

Example 21

199 mg of 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-3-(4-hydroxybutyl)quinolin-4(1H)-one was dissolved in 11 ml of 1,2-dichloroethane, and 257 mg of triphenylphosphine and 405 mg of carbon tetrabromide were added at room temperature, followed by stirring for 15 minutes. Aqueous saturated sodium hydrogen carbonate was added to the reaction mixture, followed by extraction with chloroform, washing with aqueous saturated sodium chloride, drying over anhydrous sodium sulfate and then concentration under a reduced pressure. The resulting residue was purified by a chromatography to obtain 78 mg of 3-(4-bromobutyl)-7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro quinolin-4(1H)-one.

Example 22

To 557 mg of 3-(4-bromobutyl)-7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoroquinolin-4(1H)-one was added 5 ml of triethylphosphite, followed by stirring at 160° C. for 4 hours. The reaction mixture was concentrated under a reduced pressure, and the resulting residue was purified by a column chromatography to obtain 240 mg of diethyl {4-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]butyl}phosphonate.

Example 23

To 2 ml of a 2 M isopropyl magnesium chloride THF solution was added 2 ml of THF and, at −78° C., 0.71 ml of diethyl [bromo(difluoro)methyl]phosphonate, followed by stirring at the same temperature for 5 minutes. A 10 ml THF solution of 358 mg of 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was added dropwise to the reaction mixture and, after gradual temperature rising to room temperature, this was stirred for 2.5 hours. Aqueous saturated sodium chloride was added to the reaction mixture, followed by extraction with chloroform and ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under a reduced pressure. Methanol was added to the residue, insoluble materials were filtered, and the resulting filtrate was evaporated under a reduced pressure. By purifying the resulting residue by a column chromatography, 257 mg of diethyl {2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydro quinolin-3-yl]-1,1-difluoro-2-hydroxyethyl}phosphonate.

Example 24

1.0 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was dissolved in 20 ml of DMF, and 2.0 g of potassium carbonate and 2.8 ml of ethyl(diethoxyphosphoryl)acetate were added, followed by overnight stirring at 60° C. The resulting reaction mixture was cooled to room temperature, water was added, and then the insoluble materials were collected by filtration to obtain 1.2 g of ethyl (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylate.

Example 25 and Example 26

500 mg of {(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]vinyl}phosphonic acid was dissolved in 10 ml of acetonitrile, and 86 mg of sodium iodide, 0.51 ml of 1,8-diazabicyclo[5.4.0]-7-undecene, 194 mg of tetrabutylammonium hydrogensulfate and 0.53 ml of chloromethyl pivalate were added in that order, followed by overnight stirring at 80° C. Aqueous saturated ammonium chloride was added to the reaction mixture, followed by extraction with chloroform. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and then evaporated under a reduced pressure. By purifying the resulting residue by silica gel column chromatography, 400 mg of bis{[(2,2-dimethylpropanoyl)oxy]methyl}{(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]vinyl}phosphonate (Example 25) and 190 mg of {[{(E)-2-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydro-3-quinolinyl]vinyl}(hydroxy)phosphoryl]oxy}methyl pivalate (Example 26) were obtained.

Example 27

To a 5.0 ml DMF solution of 144 mg of 7-(cyclohexylamino)-6-fluoro-3-hydroxy-1-isopropylquinolin-4(1H)-one were added 313 mg of potassium carbonate and 100 μl of ethyl bromoacetate in that order, followed by overnight stirring at room temperature. Aqueous saturated ammonium chloride was added to the reaction mixture, followed by extraction with ethyl acetate. After drying over anhydrous sodium sulfate and subsequent evaporation under a reduced pressure, the residue was purified by silica gel column chromatography to obtain 159 mg of ethyl {[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}acetate.

Example 28

To a 2.9 ml dioxane solution of tert-butyl (2-{[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-2-oxoethyl)carbamate was added 3.0 ml of a 4M hydrogen chloride dioxane solution, followed by overnight stirring at room temperature. The insoluble materials were collected by filtration to obtain 550 mg of 2-amino-N-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acetamide hydrochloride.

Example 29

To a 90 ml DMF solution of 15.0 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was added 9.9 g of 1,1′-carbonyldiimidazole, followed by stirring at 80° C. for 24 hours. After cooling, the reaction mixture was poured into ice water, and the solid precipitated was collected by filtration. Next, 1.9 g of sodium borohydride was added at 0° C. to a mixed solution of 200 ml THF and 100 ml water of the resulting solid, followed by stirring at the same temperature for 2 hours. Water was added, the solvent was evaporated under a reduced pressure, and the insoluble materials were collected by filtration to obtain 13.8 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(hydroxymethyl)quinolin-4(1H)-one.

Example 30

After adding 0.32 ml of DMSO to a 7.0 ml dichloromethane solution of 0.20 ml of oxalyl dichloride at −78° C. and stirring for 30 minutes, a dichloromethane solution of 330 mg of N-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]-2-(hydroxymethyl)butanamide was added at −78° C., followed by stirring for 30 minutes. Next, 1.2 ml of triethylamine was added thereto, and the temperature was risen from −78° C. to room temperature spending 2 hours. Aqueous saturated sodium chloride was added to the reaction mixture, followed by extraction with ethyl acetate, drying over anhydrous sodium sulfate, and evaporation under a reduced pressure, thereby obtaining 320 mg of crude product of N-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]-2-formylbutanamide. To a 6.4 ml dichloromethane solution of 320 mg of the resulting crude product was added 290 mg of methyl(triphenylphosphoranilidene)acetate, followed by overnight stirring at room temperature. By evaporating the reaction mixture under a reduced pressure and purifying the resulting mixture by silica gel column chromatography, 220 mg of methyl (2E)-4-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}carbonyl)hex-2-enoate was obtained.

Example 31

To a 8 ml THF solution of 400 mg of ethyl 3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]propanoate was added 40 mg of lithium aluminum hydride at 0° C., followed by stirring for 2 hours. Water was added to the reaction mixture, followed by and filteraion through celite. After evaporation under a reduced pressure, the resulting residue was purified by silica gel column chromatography to obtain 288 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(3-hydroxypropyl)quinolin-4(1H)-one.

Example 32

To a 5 ml 1,4-dioxane solution of 300 mg of {[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}acetonitrile was added 0.8 ml of tributyltin azide, followed by heating under reflux for 2 days. After cooling to room temperature, aqueous 1M sodium hydroxide solution and ether were added, followed by layer separation operation. To the aqueous layer was added 1 M hydrochloric acid, followed by extraction with chloroform and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under a reduced pressure. By adding ether to the resulting residue and collecting the insoluble materials by filtration, 70 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(1H-tetrazol-5-ylmethoxy)quinolin-4(1H)-one was obtained.

Example 33

To a 30 ml dichloromethane suspension of 3.69 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide were added at −78° C. 7.0 ml of triethylamine and a 10 ml dichloromethane solution of 4.0 ml of trifluoroacetic anhydride. After gradually rising the temperature, it was stirred at room temperature for 2 days. After adding water, it was extracted with chloroform, followed by drying over anhydrous sodium sulfate. After filtration, the solvent was evaporated under a reduced pressure and the resulting residue was purified by silica gel column chromatography. After adding a mixed solvent of 30 ml of THF, 30 ml of methanol and 10 ml of water to the resulting solid, 2.3 g of potassium carbonate was added thereto under ice-cooling. After stirring at room temperature for 15 hours, 1.0 g of potassium carbonate was added thereto, followed by stirring at room temperature for 4 days. After evaporating the solvent under a reduced pressure, water was added, followed by extraction with chloroform. After drying over anhydrous sodium sulfate and subsequent filtration, the solvent was evaporated under a reduced pressure. By washing the resulting residue with ethyl acetate, 2.62 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile was obtained.

Example 34

10 ml of Raney nickel was washed three times with ethanol. 30 ml of ethanol, 3 ml of aqueous ammonia and 2.5 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile were added thereto, followed by overnight stirring in an atmosphere of hydrogen. After addition of chloroform and subsequent filtration using celite, the solvent was evaporated under a reduced pressure. The resulting residue was dissolved in 20 ml of THF, a 10 ml THF solution of 1.8 g of di-tert-butyl dicarbonate was added under ice-cooling, followed by overnight stirring at room temperature. A 10 ml THF solution of 1.0 g of di-tert-butyl dicarbonate was added thereto under ice-cooling, followed by stirring at room temperature for 3 days. A 10 ml THF solution of 1.0 g of di-tert-butyl dicarbonate was added thereto under ice-cooling, followed by overnight stirring at room temperature. After evaporation of the solvent under a reduced pressure and subsequent purification by silica gel column chromatography, the resulting solid was recrystallized from hexane-ethyl acetate to obtain 1.22 g of tert-butyl {[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}carbamate.

Example 35

To 5.50 g of 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile were added 50 ml of ethanol, 3.0 ml of concentrated hydrochloric acid and 0.60 g of platinum oxide, followed by overnight stirring in an atmosphere of hydrogen. After adding water, celite filtration was carried out and the solvent was evaporated under a reduced pressure. The resulting residue was dissolved by adding 30 ml of water and 20 ml of THF, and 4.0 g of sodium hydrogen carbonate and 4.5 g of di-tert-butyl dicarbonate were added under ice-cooling, followed by stirring under ice-cooling for 1 hour and overnight at room temperature. After evaporation of the solvent under a reduced pressure, water was added, followed by extraction with chloroform and drying over anhydrous sodium sulfate. After filtration, the solvent was evaporated under a reduced pressure and the resulting residue was purified by silica gel column chromatography to obtain 5.72 g of tert-butyl {[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}carbamate.

Example 36

To 0.31 g of 7-(cyclohexylamino)-6-fluoro-4-oxo-1-pyrrolidin-3-yl-1,4-dihydroquinoline-3-carbonitrile hydrochloride were added 5 ml of ethanol, 0.2 ml of concentrated hydrochloric acid and 0.10 g of platinum oxide, followed by overnight stirring in an atmosphere of hydrogen. After adding water, celite filtration was carried out and the solvent was evaporated under a reduced pressure. By purifying the resulting residue by an ODS column chromatography, 256 mg of 3-(aminomethyl)-7-(cyclohexylamino)-6-fluoro-1-pyrrolidin-3-ylquinolin-4(1H)-one hydrochloride was obtained.

Example 37

To a 40 ml DMSO solution of 2.0 g of 1-cyclopentyl-6,7-difluoro-3-nitroquinolin-4(1H)-one was added 2.3 ml of cyclohexylamine, followed by overnight stirring at 90° C. The reaction mixture was cooled to room temperature and poured into ice-cooled water, and then the insoluble materials were collected by filtration. By recrystallizing the resulting solid from ethanol, 2.5 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-nitroquinolin-4(1H)-one was obtained.

Example 38

To a 4 ml ethanol solution of 220 mg of 3-amino-7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoroquinolin-4(1H)-one was added 105 mg of 1H-1,2,3-benzotriazol-1-ylmethanol, followed by overnight stirring at room temperature. Next, 48 mg of sodium borohydride was added to the reaction mixture, followed by stirring for 3 hours. By adding water to the resulting reaction mixture and collecting the insoluble materials by filtration, 100 mg of 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-3-(methylamino)quinolin-4(1H)-one was obtained.

Example 39

To a 100 ml dichloromethane solution of 13.8 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(hydroxymethyl)quinolin-4(1H)-one was added 67.0 g of manganese dioxide at room temperature, followed by overnight stirring. After completion of the reaction and subsequent filtration using celite, the filtrate was evaporated under a reduced pressure. By crystallizing the resulting solid from ethyl acetate, 13.0 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was obtained.

Example 40

6.1 g of metachloroperbenzoic acid was gradually added to a 100 ml of dichloromethane solution of 8.0 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde at room temperature, followed by stirring for 2 hours. Aqueous saturated sodium hydrogen carbonate and aqueous sodium hydrogenthiosulfate were added to the reaction mixture, followed by stirring for 30 minutes and then extraction with chloroform. After drying over anhydrous sodium sulfate and subsequent evaporation under a reduced pressure, the residue was purified

(Production Methods)

The compound of the present invention and a pharmaceutically acceptable salt thereof may be produced by employing various conventionally known synthesis methods making use of the characteristics based on its basic skeleton or kind of the substituent groups. Typical production methods are exemplified in the following. In this connection, depending on the kinds of functional group, there is an effective case from the production technology point of view to replace said functional group with an appropriate protecting group, namely a group which may be easily converted into said functional group, at the stage of starting material to intermediate. Thereafter, the desired compound may be obtained by removing the protecting group as occasion demands. Examples of the functional group include hydroxyl group, carboxyl group, amino group and the like, and as their protecting groups, the protecting groups described for example in “Protective Groups in Organic Synthesis (third edition)” edited by Greene and Wuts, may be cited, which may be optionally used in response to the reaction conditions.

First Production Method

(In the formulae, L¹ represents a leaving group such as halogen, —O-methanesulfonyl, —O-p-toluenesulfonyl or the like. The same shall apply hereinafter.) by silica gel column chromatography to obtain 7.7 g of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-hydroxyquinoline-4(1H)-one.

Example 41

To a 2.0 ml acetic acid solution of 150 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde were added 60 mg of 2-thioxo-1,3-thiazoline-4-one and 40 mg of sodium acetate in that order, followed by overnight stirring at 100° C. The reaction mixture was cooled to room temperature and evaporated under a reduced pressure. Ethyl acetate was added, and the insoluble materials were collected by filtration to obtain 173 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-[(Z)-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]quinolin-4(1H)-one.

Example 42

To a 15 ml THF solution of 762 mg of 3-(3-{[tert-butyl(dimethyl)silyl]oxy}propoxy)-7-(cyclohexylamino)-1-cyclopentyl-6-fluoroquinoline-4(1H)-one was added 1.5 ml of a 1 M tetrabutylammonium fluoride THF solution at room temperature, followed by stirring for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, evaporation was carried out under a reduced pressure. By purifying the residue by silica gel column chromatography, 273 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(3-hydroxypropoxy)quinolin-4(1H)-one was obtained.

Example 43

To a 10 ml THF solution of 500 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-N-methoxy-N-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide was added 1.2 ml of a 1 M methyl lithium THF solution, followed by stirring at room temperature for 3 days. Water was added to the reaction mixture to carry out celite filtration. After evaporation under a reduced pressure, the resulting residue was purified by silica gel column chromatography to obtain 150 mg of 3-acetyl-7-(cyclohexylamino)-1-cyclopentyl-6-fluoroquinolin-4(1H)-one.

Example 44

To a 5.0 ml dichloromethane solution of 500 mg of 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde were added 0.23 ml of diethyl phosphite and 0.22 ml of 1,8-diazabicyclo[5.4.0]-7-undecene at −40° C., followed by overnight stirring at room temperature. Aqueous saturated ammonium chloride was added to the reaction mixture, followed by extraction with chloroform and then washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent evaporation under a reduced pressure, the resulting residue was purified by silica gel column chromatography to obtain 400 mg of diethyl [[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl](hydroxy)methyl]phosphonate.

Example 45

To a 3.2 ml DMF solution of 160 mg of ethyl {[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydro quinolin-3-yl]amino}acetate were added 0.05 ml of benzyl bromide and 75 mg of potassium carbonate, followed by overnight stirring at room temperature. By adding water to the reaction mixture and collecting the insoluble materials by filtration, 200 mg of ethyl {benzyl[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydro quinolin-3-yl]amino}acetate was obtained.

Example 46

To a 4.2 ml THF solution of 210 mg of (2E)-3-{7-[(cyclopropylmethyl)amino]-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl}acrylic acid was added 120 mg of 1,1′-carbonyldiimidazole, followed by overnight stirring at room temperature. Water was added to the reaction mixture and the insoluble materials were collected by filtration. The resulting solid was dissolved in 4.2 ml of DMF, and 0.11 ml of 1,8-diazabicyclo[5.4.0]-7-undecene and 150 mg of 5-chlorothiophene-2-sulfonamide were added, followed by overnight stirring at 80° C. By adding water to the resulting reaction mixture and collecting the insoluble materials by filtration, 145 mg of (2E)-N-[(5-chloro-2-thienyl)sulfonyl]-3-{7-[(cyclopropylmethyl)amino]-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl}acrylamide was obtained.

Example 47

Under ice-cooling, 2.0 ml of trifluoroacetic acid was added to a 5 ml dichloromethane solution of 0.20 g of tert-butyl {[7-(cyclohexylamino)-6-fluoro-4-oxo-1-(tetrahydrofuran-3-yl)-1,4-dihydroquinolin-3-yl]methyl}carbamate. After stirring under ice-cooling for 1.5 hours and at room temperature overnight, the solvent was evaporated under a reduced pressure. By purifying the resulting residue by an ODS column chromatography, 184 mg of 3-(aminomethyl)-7-(cyclohexylamino)-6-fluoro-1-tetrahydrofuran-3-yl)quinolin-4(1H)-one trifluoroacetate was obtained.

Example 48

To a 4.8 ml DMSO solution of 240 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(3-hydroxypropyl)quinolin-4(1H)-one were added 300 mg of a sulfur trioxide pyridine complex and 0.8 ml of triethylamine, followed by overnight stirring at room temperature. Water was added to the reaction mixture, followed by extraction with chloroform and then washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent evaporation under a reduced pressure, the resulting residue was purified by silica gel column chromatography to obtain 140 mg of an aldehyde compound. To a 2.8 ml DMF solution of 140 mg of the aldehyde compound were added 141 mg of potassium carbonate and 414 mg of ethyl (diethoxyphosphoryl)acetate, followed by overnight stirring at 60° C. The reaction mixture was cooled to room temperature, water was added, and the insoluble materials were collected by filtration. By purifying the resulting insoluble materials by silica gel column chromatography, 57 mg of ethyl (2E)-5-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]pent-2-enoate was obtained.

Example 49

3 ml of ethyl acetate and 0.35 ml of a 1 M hydrogen chloride ethyl acetate solution were added to 0.13 g of ethyl({[7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)acetate obtained by the same method of Example 9. After evaporation of the solvent under a reduced pressure and subsequent addition of ether, the insoluble materials were collected by filtration to obtain 97 mg of ethyl({[7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)acetate hydrochloride.

Example 50

10 ml of ethyl acetate, 45 mg of oxalic acid and 10 ml of ethanol were added to 440 mg of ethyl({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-(tetrahydrofuran-3-yl)-1,4-dihydroquinolin-3-yl]methyl}amino)acetate obtained by the same method of Example 4. After evaporation of the solvent under a reduced pressure and subsequent addition of ethyl acetate, the insoluble materials were collected by filtration to obtain 349 mg of ethyl({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-(tetrahydrofuran-3-yl)-1,4-dihydroquinolin-3-yl]methyl}amino)acetate oxalate.

Example 51

To 0.25 g of ethyl({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-(tetrahydrofuran-3-yl)-1,4-dihydroquinolin-3-yl]methyl}amino)acetate oxalate were added water and potassium carbonate, followed by extraction with chloroform. After drying over anhydrous sodium sulfate and subsequent filtration, the solvent was evaporated under a reduced pressure. To a 10 ml ethanol solution of the resulting residue was added 0.60 ml of aqueous 1 M sodium hydroxide solution under ice-cooling, followed by stirring under ice-cooling for 1 hour and at room temperature overnight. After evaporation of the solvent under a reduced pressure, water and trifluoroacetic acid were added. By purifying by an ODS column chromatography, 251 mg of ({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-(tetrahydro furan-3-yl)-1,4-dihydroquinolin-3-yl]methyl}amino)acetic acid trifluoroacetate was obtained.

Example 52

To a 2.0 ml chloroform solution of 155 mg of diethyl [2-(acetyl{[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)-1,1-difluoeoethyl]phosphonate was added 0.27 ml of bromotrimethylsilane, followed by overnight stirring at room temperature. The reaction mixture was evaporated under a reduced pressure, and aqueous 1 M sodium hydroxide solution was added to the resulting residue, followed by purification by an ODS column chromatography and washing with ethyl acetate to obtain 100 mg of disodium [2-(acetyl {[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)-1,1-difluoeoethyl]phosphonate.

Example 53

To an 8.0 ml ethanol solution of 280 mg of ethyl (2E)-4-{[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}but-2-enoate was added 28 mg of rhodium-carbon (10%) at room temperature, followed by stirring for 2 hours in an atmosphere of hydrogen. After filtration using celite, the filtrate was evaporated under a reduced pressure, and the residue was purified by silica gel column chromatography to obtain 202 mg of ethyl 4-{[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}butanoate.

Example 54

To a 1.0 ml THF-1.0 ml methanol mixed solution of 130 mg of N-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]-2-[(4R)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetamide was added 0.3 ml of 1 M hydrochloric acid, followed by overnight stirring at room temperature. Then, 0.8 ml of aqueous 1M sodium hydroxide solution was added, followed by overnight stirring at room temperature. The resulting reaction mixture was neutralized with 1 M hydrochloric acid, and then the insoluble materials were collected by filtration and purified by silica gel column chromatography to obtain 11 mg of (2R)-4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-2-hydroxy-4-oxobutanoic acid.

Example 55

To a 2.0 ml THF solution of 100 mg of (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylic acid was added 60 mg of 1,1′-carbonyldiimidazole, followed by overnight stirring at room temperature. By adding water to the resulting reaction mixture and collecting the insoluble materials by filtration, an acylimidazole compound was obtained. To a 2.0 ml DMF solution of the resulting acylimidazole compound was added 0.5 ml of aqueous ammonia, followed by overnight stirring at 60° C. The resulting reaction mixture was cooled to room temperature, water was added, and the insoluble materials were collected by filtration to obtain 58 mg of (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylamide.

Example 56

To a 5.0 ml ethanol solution of 500 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was added 215 mg of ethyl aminoacetate hydrochloride, followed by stirring at room temperature for 2 hours. Next, 50 mg of palladium-carbon was added thereto, followed by stirring at room temperature for 4 hours in an atomosphere of hydrogen. The reaction mixture was filtered through celite and then evaporated under a reduced pressure. The resulting residue was purified by silica gel column chromatography. To a 3.6 ml dioxane solution of the resulting compound was added 4.0 ml of a 4 M hydrogen chloride dioxane solution, followed by overnight stirring at room temperature. The insoluble materials were collected by filtration to obtain 320 mg of ethyl({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}amino)acetate hydrochloride.

Example 57

2.0 ml of THF and 0.071 ml of chlorotrimethylsilane were added to 73 mg of zinc, followed by stirring at room temperature for 15 minutes. Then, 200 mg of ethyl (2E)-4-bromobut-2-enoate was added thereto, followed by stirring at room temperature for 30 minutes. To the reaction mixture was added 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydro quinoline-3-carbaldehyde, followed by overnight stirring at room temperature. Water was added to the reaction mixture, followed by extraction with chloroform. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate and then evaporated under a reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain 30 mg of ethyl (2E)-5-[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]-5-hydroxypent-2-enoate.

Example 58

To a 5 ml THF solution of 119 mg of 60% sodium hydride was added 598 μl of ethyl(diethoxyphosphoryl)acetate at 0° C., followed by stirring for 30 minutes. A 5 ml THF solution of 400 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(2-oxopropoxy)quinolin-4(1H)-one was added thereto at the same temperature, followed by stirring at room temperature for 2 hours. To the reaction mixture was added aqueous saturated ammonium chloride, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated under a reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain 200 mg of ethyl (2E)-4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-methylbut-2-enoate.

Example 59

To a 20 ml THF suspension of 1081 mg of (3-benzyloxypropyl)triphenylphosphonium bromide was added 258 mg of potassium, tert-butoxide followed by stirring for 1.5 hours. A 10 ml THF solution of 358 mg of 7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde was added thereto, followed by stirring for 1 hour. To the reaction mixture was added aqueous saturated ammonium chloride, followed by extraction with ethyl acetate and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent concentration under a reduced pressure, the residue was purified by silica gel column chromatography to obtain 488 mg of 3-[4-(benzyloxy)but-1-en-1-yl]-7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoroquinolin-4(1H)-one.

Example 60

To a 2 ml dichloromethane solution of 100 mg of 5-chlorothiophene-2-carboxylic acid was added 0.55 ml of chlorosulfonyl isocyanate, followed by overnight stirring at 40° C. The solvent was evaporated under a reduced pressure, and the resulting residue was dissolved in 1.5 ml of dichloromethane. Then, 150 mg of 3-amino-7-(cyclohexylamino)-1-cyclopentyl-6-fluoroquinolin-4(1H)-one and 0.91 ml of triethylamine was added, followed by overnight stirring at room temperature. Water was added to the reaction mixture, followed by extraction with chloroform. The organic layer was washed with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate and subsequent filtration, the solvent was evaporated under a reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain 64 mg of 5-chloro-N-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}sulfonyl)thiophene-2-carboxamide.

Example 61

To a 6 ml DMSO suspension of 200 mg of 60% sodium hydride was added 1.1 g of trimethylsulfoxonium iodide, followed by stirring for 30 minutes. To the reaction mixture was added 242 mg of ethyl (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylate, followed by stirring at room temperature for 1 hour and at 60° C. for 1 hour. To the reaction mixture was added water, followed by extraction with diethyl ether. The organic layer was washed with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under a reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain 55 mg of ethyl 2-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]cyclopropanecarboxylate.

Example 62

To a 30 ml methanol solution of 1.5 g of {[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}acetonitrile were added 1.1 ml of triethylamine and 540 mg of hydroxylamine hydrochloride, followed by heating under reflux for 27 hours. The solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 850 mg of 2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-N′-hydroxyethanimidamide.

Example 63

40 μl of diketene was added dropwise under ice-cooling to a 8 ml chloroform solution of 800 mg of 2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-N′-hydroxyethanimidamide, followed by stirring under ice-cooling for 6 hours. By evaporating the solvent under a reduced pressure, 180 mg of N′-(acetoacetyloxy)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}ethanidamide was obtained.

Example 64 and Example 65

5 ml of toluene and 41 mg of 60% sodium hydride were added to 180 mg of N′-(acetoacetyloxy)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}ethanidamide, followed by heating under reflux for 24 hours. The solvent was evaporated under a reduced pressure, and dilute hydrochloric acid was added to the resulting residue, followed by extraction with ethyl acetate and washing with water and aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 10 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methoxy]quinolin-4(1H)-one (Example 64) and 30 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-{[5-(2-oxopropyl)-1,2,4-oxadiazol-3-yl]methoxy}quinolin-4(1H)-one (Example 65).

Example 66

0.14 ml of N-(chlorocarbonyl) isocyanate was added dropwise at −50° C. to a 4 ml THF solution of 110 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-[(hydroxyamino)methyl]quinolin-4(1H)-one, followed by stirring at room temperature for 1 hour. 1 M hydrochloric acid was added to the reaction mixture, followed by extraction with chloroform and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 45 mg of 2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]methyl}-1,2,4-oxadiazolidine-3,5-dione.

Example 67

To a 4 ml DMSO solution of 310 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-(4-hydroxybutyl)quinolin-4(1H)-one was added 0.7 ml of triethylamine and 620 mg of a sulfur trioxide pyridine complex, followed by stirring at room temperature for 24 hours. By adding 1 M hydrochloric acid and water, the insoluble materials were collected by filtration to obtain 290 mg of 4-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]butanal.

Example 68

To 285 mg of 4-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]butanal were added 9 ml of toluene and 250 mg of methyl (triphenylphosphoranilidene)acetate, followed by stirring at 80° C. for 14 hours. The solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 260 mg of methyl (2E)-6-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]hex-2-enoate.

Example 69

To 500 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde were added 5 ml of ethanol, 460 mg of sodium acetate and 290 mg of hydroxylamine hydrochloride, followed by stirring at room temperature for 15 hours and at 70° C. for 12 hours. The solvent was evaporated under a reduced pressure, and water was added to the resulting residue, followed by extraction with chloroform and washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under a reduced pressure to obtain 300 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde oxime.

Example 70

15 ml of methanol, 15 ml of THF and 250 mg of sodium cyanoborohydride were added to 300 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbaldehyde oxime. 2 ml of a 4 M hydrogen chloride dioxane solution was added thereto under ice-cooling, followed by stirring at room temperature for 3 hours. Under ice-cooling, aqueous 1 M sodium hydroxide solution was added thereto, followed by extraction with chloroform and subsequent washing with aqueous saturated sodium chloride. After drying over anhydrous sodium sulfate, the solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 130 mg of 7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-3-[(hydroxyamino)methyl]quinolin-4(1H)-one.

Example 71

To a 50 ml THF suspension of 1.02 g of 9-(cyclohexylamino)-8-fluoro-6-oxo-2,3,4,6-tetrahydro-1H-pyrido[1,2-a]quinoline-5-carboxylic acid were added 0.5 ml of triethylamine and 0.4 ml of isobutyl chloroformate under ice-cooling, followed by stirring under ice-cooling for 1 hour. Aqueous solution (4 ml) of 431 mg of sodium borohydride was added dropwise thereto at −78° C., followed by stirring at −15° C. for 15 minutes and under ice-cooling for 30 minute. Aqueous saturated ammonium chloride was added thereto, followed by extraction with ethyl acetate and subsequent drying over anhydrous sodium sulfate. The solvent was evaporated under a reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain 495 mg of 9-(cyclohexylamino)-8-fluoro-5-(hydroxymethyl)-1,2,3,4-tetrahydro-6H-pyrido[1,2-a]quinolin-6-one.

In the same manner as in the above-mentioned Examples 1 to 71, Example compounds shown in the following Tables 10 to 73 were produced using respectively corresponding starting materials. MS data of the example compounds are shown in the following Tables 10 to 73, and NMR data of several Example compounds in Tables 74 and 75.

Structures of other compounds of the present invention are shown in Tables 76 to 83. These may be easily produced by the use of the above-mentioned production methods, and the methods described in examples or the methods obvious to those skilled in the art, or modified methods thereof.

TABLE 4

Rf RSyn R⁴ R Data 11 1 Et —C(O)NH₂ FAB: 332 12 1 —CH(Et)₂ —C(O)NH₂ FAB: 374 1 1 cPen —C(O)NH₂ FAB: 372 13 1

—C(O)NH₂ FAB: 374 14 1

—C(O)NH₂ FAB: 473 2 2 cPen —C(O)N(Me)—OMe FAB: 416 15 9, E37

—CO₂H ESI: 387 16 E37, E2

—CO₂H FAB: 401

TABLE 5

Rf RSyn R⁴ Data 10 10

ESI: 336 17 10

FAB: 350

TABLE 6

Rf RSyn R⁴ Data 18 3 iPr FAB: 269 19 3 —CH(Et)₂ ESI: 297 3 3 cPen FAB: 295 20 3

FAB: 321 21 3

FAB: 341

TABLE 7 Rf RSyn Structure Data 4 4

EI: 215 5 5

FAB: 386 22 4

ESI: 180

TABLE 8

Rf RSyn X R′ R² R³ R Data 6 6 CH F F F —CO₂Et FAB: 340 23 9 N Cl F H —CO₂H FAB: 311 24 5, 6 CH F H H —CO₂Et FAB: 304 9 9 CH F H H —CO₂H FAB: 276

TABLE 9

Rf RSyn X R² R³ Data 7 7 CH F F FAB: 391 8 8 CH F —OBn FAB: 479 25 E37 N F H FAB: 374 26 E37 CH H H FAB: 355

TABLE 10

Ex Syn R^(b) Data 72 40 H FAB: 319 27 27 —CH₂CO₂Et FAB: 405 73 2 —CH₂CO₂H FAB: 377 74 27

ESI: 431 75 2

FAB: 403 53 53 —(CH₂)₃CO₂Et FAB: 433 76 2 —(CH₂)₃CO₂H FAB: 405 77 46 —CH(Me)C(O)NH—S(O)₂Me FAB(Neg): 466 78 46 —CH(Me)C(O)NH—S(O)₂Ph FAB: 530 79 12

FAB: 477 80 2

FAB: 449 81 12

FAB: 405 82 2

FAB: 391 83 Rfl

FAB: 390 84 12

ESI: 461 85 2

FAB: 433

TABLE 11 86 12

FAB: 557 87 2

ESI: 467 88 27

FAB: 445 89 2

FAB: 417

TABLE 12

Ex Syn R³ R^(b) Data 90 40 F H FAB: 365 91 27 —CH₂CO₂Et FAB: 451 92 2 —CH₂CO₂H FAB: 518 93 40 H H FAB: 347 94 27 —CH₂CO₂Et FAB: 433 95 2 —CH₂CO₂H FAB: 405 96 27

FAB: 459 97 27 —(CH₂)₃—P(O)(OEt)₂ FAB: 525 98 18 —(CH₂)₃—PO₃H₂ FAB: 469 99 12

FAB: 433 100 2

FAB: 419

TABLE 13

Ex Syn R^(b) Data 40 40 H FAB: 345 101 27 —CH₂CO₂Et FAB: 431 102 2 —CH₂CO₂H FAB: 403 103 27 —C(Me)₂CO₂Et FAB: 459 104 2 —C(Me)₂CO₂H FAB: 431 105 11 —(CH₂)₃CO₂Et FAB: 459 106 2 —(CH₂)₃CO₂H FAB: 431 107 27

FAB: 457 108 2

FAB: 429 109 24

FAB: 519 110 11 —CH₂CH(Ph)CH₂CO₂Me FAB: 521 111 2 —CH₂CH(Ph)CH₂CO₂H FAB: 507 112 12

FAB: 583 113 2

FAB: 493 12 12

FAB: 583 114 2

FAB: 493 115 12

FAB: 507 116 2

FAB: 479 117 13

FAB: 446

TABLE 14 118 14

FAB: 465 14 14

FAB: 465 13 13

FAB: 446 119 27 —CH₂C(O)Ph FAB: 463 120 12 —(CH₂)₃—OTBDMS FAB: 517 121 27 —(CH₂)₂—OH FAB: 389 42 42 —(CH₂)₃—OH ESI: 403 122 12

FAB: 535 123 2

FAB: 507 124 12

FAB: 431 125 2

FAB: 417 126 27

FAB: 459 127 2

FAB: 431 128 12

FAB: 431 129 2

FAB: 417 130 12

FAB: 487 131 2

FAB: 459 132 12

FAB: 499 133 2

FAB: 485

TABLE 15 134 12

FAB: 457 135 2

ACPI: 443 136 53

FAB: 459 137 2

FAB: 445 138 12

FAB: 503 139 2

FAB: 475 140 27 —CH₂CN FAB: 384 32 32

FAB: 427 141 2

FAB: 443 142 27

FAB: 401 58 58

FAB: 471 143 53

FAB: 445 144 2

FAB: 445 145 12 —(CH₂)4—CO₂Me FAB: 459 146 2 —(CH₂)4—CO₂H FAB: 445 147 12

FAB: 471 148 2

FAB: 443 149 53

FAB: 445

TABLE 16 62 62

FAB: 417 63 63

FAB: 501 64 64

FAB: 443 65 65

FAB: 483 150 27

FAB: 493 151 2

FAB: 479

TABLE 17

Ex Syn R⁴ R^(b) Data 152 153 154 40 27 2

H —CH₂CO₂Et —CH₂CO₂H FAB: 371 FAB: 457 FAB: 429 155 156 157 40 27 2

H —CH₂CO₂Et —CH₂CO₂H FAB: 359 FAB:: 445 FAB: 417 158 40 —CH₂CF₃ H FAB: 359 159 27 —CH₂CO₂Et ESI: 445 160 2 —CH₂CO₂H FAB: 417 161 162 163 40 27 2

H —CH₂CO₂Et —CH₂CO₂H FAB: 373 FAB:: 459 FAB: 431

TABLE 18

Ex Syn R^(b) Data 164 40 H FAB: 363 165 12

FAB: 449 166 2

FAB: 435

TABLE 19

Ex Syn R^(b) Data 167 40 H ESI: 327 168 2

FAB: 399 169 2

FAB: 413 170 12

FAB: 413 171 12

ESI: 427

TABLE 20

Ex Syn R⁴ R⁵ Data 172 37 iPr —NO₂ ESI: 320 173 11 —NH₂ ESI: 290 174 37 —CH(Et)₂ —NO₂ ESI: 348 175 11 —NH₂ ESI: 318 176 37 cPen —NO₂ FAB: 346 177 11 —NH₂ ESI: 316

TABLE 21

Ex Syn R⁴ R⁵ Data 178 37 iPr —NO₂ ESI: 348 179 11 —NH₂ ESI: 318 180 37 —CH(Et)₂ —NO₂ FAB: 376 181 11 —NH₂ FAB: 346 38 38 —NHMe FAB: 360 182 9 —NHCH₂CO₂Et FAB: 432 183 2 —NHCH₂CO₂H ESI: 404 45 45 —N(Bn)CH₂CO₂Et FAB: 522 184 2 —N(Bn)CH₂CO₂H ESI: 494 185 10 —N(Bz)CH₂CO₂Et FAB: 536 186 2 —N(Bz)CH₂CO₂H FAB: 508 187 5

ESI: 514 37 37 cPen —NO₂ FAB: 374 188 11 —NH₂ FAB: 314 189 9,2

ESI: 416 60 60

ESI(neg): 565 190 191 37 11

—NO₂ —NH₂ FAB: 400 FAB: 370 192 193 37 11

—NO₂ —NH₂ FAB: 420 FAB: 390

TABLE 22

Ex Syn R¹ R⁴ Data 194 8 cPr—CH₂— iPr FAB: 513 195 8 cPen ESI: 539 8 8 cHex iPr ESI: 541 196 8 —CH(Et)₂ FAB: 569 197 8 cPen FAB: 567

TABLE 23

Ex Syn R⁴ R^(e) Data 198 8 iPr —SO₂—Ph FAB: 501 199 8 —SO₂—Me FAB: 439 200 8

FAB: 535 7 7 —CH(Et)₂ —(CH₂)₂—CO₂Et FAB: 489 201 2 —(CH₂)₂—CO₂H ESI: 461 202 7 cPen —(CH₂)₂—CO₂H ESI: 459 203 2 —(CH₂)₂—CO₂Et FAB: 487 204 7

FAB: 521 205 2

FAB: 507 206 7 —CH(Me)CH₂CO₂Et FAB: 501 207 2 —CH(Me)CH₂CO₂H FAB: 473

TABLE 24

Ex Syn R⁶ R^(d) Data 208 1 Me —(CH₂)₂—CO₂Et FAB: 488 209 2 —(CH₂)₂—CO₂H FAB: 460 10 10 —CH₂CO₂Et —(CH₂)₃—CO₂Et FAB: 574 210 2 —CH₂CO₂H —(CH₂)₃—CO₂H FAB: 518

TABLE 25

Ex Syn R⁴ R^(d) Data 211 1 iPr —(CH₂)₃—CO₂Et FAB: 432 212 2 —(CH₂)₃—CO₂H FAB: 404 213 1 —CH(Et)₂ —(CH₂)₃—CO₂Et FAB: 460 214 2 —(CH₂)₃—CO₂H FAB: 432 215 1 cPen —(CH₂)₃—CO₂Et ESI: 458 216 2 —(CH₂)₃—CO₂H FAB: 430 217 1

FAB: 478 218 2

FAB: 492

TABLE 26

Ex Syn R⁴ R^(d) Data 219 1 iPr —(CH₂)₂—CO₂Et FAB: 446 220 2 —(CH₂)₂—CO₂H FAB: 418 221 1 —(CH₂)₃—CO₂Et FAB: 460 222 2 —(CH₂)₃—CO₂H FAB: 432 223 1 —(CH₂)₃—CO₂—(CH₂)₂—NMe₂ FAB: 503 224 2

FAB: 460 225 1

FAB: 446 226 227 2 1

—(CH₂)₃—CO₂Et —(CH₂)₃—CO₂H FAB: 512 FAB: 484 228 229 2 1

—(CH₂)₃—CO₂Et —(CH₂)₃—CO₂H FAB: 532 FAB: 504

TABLE 27

Ex Syn R^(d) Data 230 1 —CH₂CO₂Et FAB: 460 231 2 —CH₂CO₂H FAB: 432 232 1 —(CH₂)₂CO₂Et FAB: 474 233 2 —(CH₂)₂CO₂H FAB: 446 234 1 —(CH₂)₃CO₂Et FAB: 488 235 2 —(CH₂)₃CO₂H FAB: 460 236 1, 2 —(CH₂)₄—CO₂H FAB: 474 237 2

FAB: 474 238 1

FAB: 460 239 2 —CH(Et)CO₂Et FAB: 488 240 1 —CH(Et)CO₂H FAB: 460 241 2 —C(Me)₂CO₂Et FAB: 488 242 1 —C(Me)₂CO₂H FAB: 460 243 2

FAB: 488 244 1

FAB: 474 245 2 —CH₂CH(Me)CH₂CO₂Me FAB: 488 246 1 —CH₂CH(Me)CH₂CO₂H FAB: 474 30 30

FAB: 500 247 11 —CH(Et)—(CH₂)₂—CO₂Me FAB: 502 248 2 —CH(Et)—(CH₂)₂—CO₂H FAB: 488 249 1

FAB: 458

TABLE 28 250 1

FAB: 458 251 2

FAB: 476 252 2

FAB: 476 253 1 —(CH₂)₂—CH(Ph)CO₂Et ESI: 564 254 2 —(CH₂)₂—CH(Ph)CO₂H ESI: 536 255 2 —CH₂CH(Ph)CH₂CO₂H FAB: 536 256 1 —CH₂CH(Ph)CH₂CO₂Et FAB: 564 257 1 —CH₂OCH₂CO₂Et ESI: 490 258 2 —CH₂OCH₂CO₂H FAB: 462 9 9

ESI: 575 259 2

ESI: 519 260 2 —(CH₂)₂—P(O)(OEt)₂ FAB: 538 261 52 —(CH₂)₂—PO₃Na₂ FAB: 482 (M⁺ − 2Na + 3) 262 1 —CH₂NHBoc FAB: 503 28 28 —CH₂NH₂ FAB: 403; Sal: 2HCl 263 29 —CH(Et)CH₂OH FAB: 446 264 2

ESI: 498 265 2

FAB: 500 266 1

FAB: 512

TABLE 29 267 11

ESI: 514 268 1

FAB: 594 269 2

FAB: 538

TABLE 30

Ex Syn R^(d) Data 1 1 —(CH₂)₂—CO₂Et FAB: 472 2 2 —(CH₂)₂—CO₂H FAB: 444 270 1 —(CH₂)₃—CO₂Et FAB: 486 271 2 —(CH₂)₃—CO₂H FAB: 458 272 1 —(CH₂)₄—CO₂Et FAB: 500 273 2 —(CH₂)₄—CO₂H FAB: 472 274 1

FAB: 470 275 2

FAB: 442 276 1

APCI: 486 277 2

FAB: 472 278 1

FAB: 500 54 54

FAB: 460 279 1 —CH₂CH(Ph)CH₂CO₂Et FAB: 562 280 2 —CH₂CH(Ph)CH₂CO₂H FAB: 534 281 1 —(CH₂)₂—P(O)(OEt)₂ FAB: 536 282 3 —(CH₂)₂—PO₃H₂ FAB: 480 Sal: HBr 283 1

FAB: 506

TABLE 31 284 2

FAB: 492 285 1

FAB: 506 286 2

FAB: 492 287 1

FAB: 592 288 2

FAB: 564 289 2

FAB: 536 290 10 —CO₂Et FAB: 444 291 2 —CO₂H ESI: 416 292 2

FAB: 474 293 1

ESI: 544

TABLE 32

Ex Syn R⁴ R⁵ Data 294 29 cPen —CH₂OH FAB: 331 295 39 —CHO FAB: 329 296 24

FAB: 399 297 2

ESI: 371 298 29 iPr —CH₂OH FAB: 305 299 39 —CHO FAB: 303 300 24

FAB: 373 301 2

FAB: 345 46 46

FAB: 524

TABLE 33

Ex Syn R³ R⁵ Data 302 29 F —CH₂OH FAB: 379 303 39 —CHO FAB: 377 304 24

FAB: 447 305 2

FAB: 419 306 29 —OBn —CH₂OH ESI: 467 307 11 —OH —CH₂OH ESI: 377 308 39 —CHO FAB Neg): 373 309 24

FAB: 445 310 2

FAB: 417 311 2

ESI: 532 312 2

FAB: 560 313 1

FAB: 588 314 24

ESI: 509 315 3

ESI: 453 Sal: HBr

TABLE 34

Ex Syn R⁴ R⁵ Data 316 29 Et —CH₂OH FAB: 319 317 39 —CHO FAB: 317 318 29 iPr —CH₂OH FAB: 333 319 39 —CHO FAB: 331 320 24

FAB: 401 321 2

ESI: 373 322 41

FAB: 446 323 46

FAB: 450 324 46

FAB: 512 325 55

ESI: 506 326 29

—CH₂OH FAB: 361 327 328 329 330 29 39 24 2

—CH₂OH —CHO

FAB: 361 FAB: 359 FAB: 429 FAB: 401 331 332 333 334 29 39 24 2

—CH₂OH —CHO

FAB: 361 FAB: 359 FAB: 429 FAB: 401

TABLE 35 335 28

—CH₂OH FAB: 360 Sal: 2HCl 336 5

—CH₂OH FAB: 374 337 29

—CH₂OH FAB: 460 338 29

—CH₂OH FAB: 438 339 29

—CH₂OH FAB: 388 340 29 —CH(Me)(cBu) —CH₂OH FAB: 373 341 39 —CHO FAB: 371 342 29 —CH₂CF₃ —CH₂OH FAB: 373 343 39 —CHO FAB: 371 344 345 29 39

—CH₂OH —CHO FAB: 387 FAB: 385 346 347 29 39

—CH₂OH —CHO FAB: 385 FAB: 383

TABLE 36

Ex Syn R⁵ Data 348 29 —CH₂OH FAB: 361 349 39 —CHO FAB: 359 350 11 —(CH₂)₄—OH FAB: 403 351 6

ESI(Neg): 427 352 29

ESI: 387 59 59

FAB: 491 353 24

FAB: 429 354 2

FAB: 401 355 11 —(CH₂)₂—CO₂Et FAB: 431 356 2 —(CH₂)₂—CO₂H FAB: 403 357 24

ESI(Neg): 445 358 2

FAB: 419 359 24

ESI(Neg): 461 360 2

FAB: 435 57 57

ESI: 473 361 2

FAB: 445 362 1

FAB: 486 363 2

FAB:458

TABLE 37 364 1

FAB: 572 365 2

ESI: 514 366 2

FAB: 516 367 11

FAB: 574 368 2

ESI(Neg): 516 369 11 —(CH₂)₂—P(O)(OEt)₂ FAB: 495 370 18 —(CH₂)₂—PO₃H₂ FAB: 439 21 21 —(CH₂)₄—Br FAB: 465 22 22 —(CH₂)₄—P(O)(OEt)₂ FAB: 523 371 18 —(CH₂)₄—PO₃H₂ FAB: 467 Sal: HCl 44 44 —CH(OH)P(O)(OEt)₂ FAB: 497 372 18 —CH(OH)PO₃H₂ FAB: 441 23 23 —CH(OH)CF₂P(O)(OEt)₂ ESI(Neg): 545 373 18 —CH(OH)CF₂PO₃H₂ FAB: 491 374 24

FAB: 493 3 3

FAB: 437 Sal: HBr 18 18

FAB: 437

TABLE 38

Ex Syn R^(pa) R^(pb) Data 375 26 H —CH₂OC(O)OiPr FAB: 553 26 26 H —CH₂OC(O)OtBu FAB(Neg): 549 25 25 —CH₂OC(O)OtBu —CH₂OC(O)OtBu FAB: 665 376 25 —CH(Me)OC(O)-cHex —CH(Me)OC(O)-cHex ESI: 777 377 25 —CH(Me)OC(O)-tBu —CH(Me)OC(O)-tBu FAB: 693

TABLE 39

Ex Syn R⁵ Data 29 29 —CH₂OH FAB: 359 39 39 —CHO FAB: 357 19 19 —(CH₂)₂—OH FAB: 373 31 31 —(CH₂)₃—OH FAB: 387 43 43 Ac FAB: 371 378 2 —(CH₂)₂—CO₂H FAB: 401 16 16 —CH(OH)CO₂Me FAB: 417 15 15 —CH(OH)CO₂H FAB: 403 17 17 —CH(CO₂Me)—OCH₂CO₂Et FAB: 503 379 2 —CH(CO₂H)—OCH₂CO₂H FAB: 461 20 20 —CH₂CO₂H FAB: 387 11 11 —(CH₂)₂—CO₂Et FAB: 429 24 24

FAB: 427 380 2

FAB: 399 55 55

FAB: 398 381 57, 2

ESI: 413 382 24

FAB: 441 383 2

FAB: 413 384 24

FAB: 455 385 2

FAB: 427 386 24

FAB: 441

TABLE 40 387 2

FAB: 469 388 24

FAB: 517 389 2

FAB: 489 390 24

FAB: 445 391 2

FAB: 417 392 24

FAB: 461 393 2

ESI: 433 48 48

FAB: 455 394 2

ESI: 427 395 1

FAB: 570 396 2

ESI: 514 397 24

FAB: 491 398 3

ESI: Sal: 435 HBr 41 41

FAB: 472

TABLE 41 399 1

FAB: 504 400 11

FAB: 416 401 55

FAB: 414 61 61

FAB: 441 402 2

FAB: 413 403 41

ESI: 456 404 11

FAB: 458 69 69

FAB: 372 70 70 —CH₂NH₂OH FAB: 374 66 66

FAB: 443 405 59

FAB: 489 406 11 —(CH₂)₄—OH FAB: 401 67 67 —(CH₂)₃—CHO ESI: 399 68 68

FAB: 455 407 2

ESI: 441

TABLE 42 408 24

FAB: 380 409 32

FAB: 423

TABLE 43

Ex Syn R⁵ Data 410 29 —CH₂OH FAB: 377 411 39 —CHO FAB: 375 412 24

FAB: 445 413 2

FAB: 417

TABLE 44

Ex Syn R³ R₅ Data 414 29 —OBn —CH₂OH FAB: 465 415 11 —OH —CH₂OH FAB: 375 416 39 —OH —CHO FAB: 373 417 24 —OH

FAB: 443 418 2 —OH

ESI: 415

TABLE 45

Ex Syn R⁵ Data 419 29 —CH₂OH FAB: 341 420 39 —CHO FAB: 339 421 24

FAB: 409 422 2

FAB: 381

TABLE 46

Ex Syn R⁴ R⁵ Data 423 33 Et CN FAB: 314 424 34 —CH₂NHBoc FAB: 418 425 33 —CH(Et)₂ CN FAB: 356  35 35 —CH₂NHBoc FAB: 460 426  4

FAB: 528 427  2

FAB: 500 428  8

FAB: 583  33 33 cPen CN FAB: 354  34 34 —CH₂NHBoc FAB: 458 429  1

FAB: 456 430 431 33 34

CN —CH₂NHBoc FAB: FAB: 356 460 432 33

CN FAB: 455 433 28

CN FAB: Sal: 355 2HCl 434 435  5 35

CN —CH₂NHBoc FAB: FAB: 369 473

TABLE 47

Ex Syn R^(c) Data 436 28 H FAB: 360; Sal: 2HCl 437 9 —CH₂CO₂Et FAB: 446 438 2 —CH₂CO₂H FAB: 418 439 4 —(CH₂)₃—CO₂Et FAB: 474 440 2 —(CH₂)₃—CO₂H ESI (Neg): 444 441 4

FAB: 518 442 2

FAB: Sal: 490; AcOH 5 5 —CH(Me)CH₂P(O)(OEt)₂ ESI: 538 443 3 —CH(Me)CH₂PO₃H₂ ESI: 482; Sal: 2HBr 444 4, 49 —CH₂CF₂P(O)(OEt)₂ FAB: 560; Sal: HCl 445 3 —CH₂CF₂PO₃H₂ FAB: 504; Sal: HBr

TABLE 48

Ex Syn R⁴ R^(c) Data 446  28  Et H FAB: 318; Sal: 2HCl 49 9, 49 —CH₂CO₂Et FAB: 404; Sal: HCl 447  2 —CH₂CO₂H FAB: 376; Sal: HCl 448  4 iPr

FAB: 466 449  2

FAB: 452 450  28  cPen H FAB: 358; Sal: 2HCl 56 56  —CH₂CO₂Et FAB: 444; Sal: HCl 4 4

FAB: 450 451  4

FAB: 450 452  4

FAB: 492 453  2

FAB: 478 47   454  50   51 47    4 4, 50   51 

H   —(CH₂)₃—OH —CH₂CO₂Et   —CH₂CO₂H FAB: Sal: FAB: FAB: Sal: FAB: Sal: 360; TFA 418 418; Oxa 418; TFA 36 36 

H ESI: Sal: 359; 2HCl 455  28 

H FAB: Sal: 373; 3HCl

TABLE 49

Ex Syn R⁴ R⁶ R^(c) Data 456 2 Et Me —CH₂CO₂H FAB: 390 457 4, 49 —CH₂CO₂Et FAB: 418 Sal: HCl 458 5, 49 —CH(Et)₂ Me —CH₂CF₂P(O)(OEt)₂ FAB: 574 Sal: HCl 459 52  Me —CH₂CF₂PO₃Na₂ ESI: 518 (M⁺ − 2Na + 3) 460 9, 49 —CH₂CO₂Et —CH₂CO₂Et FAB: 532 Sal: HCl 461 2 —CH₂CO₂H —CH₂CO₂H FAB: 476

TABLE 50

Ex Syn R⁶ R^(d) Data 462 10  —CH₂CO₂Et Ph FAB: 548 463 2 —CH₂CO₂H FAB: 520 464 465 10  2 —CH₂CO₂Et —CH₂CO₂H

FAB: 564 FAB: 536 466 1 —CH₂CO₂Et

FAB: 654 467 468 11  2   —CH₂CO₂H

FAB: 564 FAB: 536

TABLE 51

Ex Syn R⁶ R^(d) Data 52 52 —CH₂CF₂PO₃Na₂ Me ESI: 546 (M⁺ − 2Na + 3) 469 6 —CH₂CF₂P(O)(OEt)₂ FAB: 602 6 6 —(CH₂)₃—CO₂Et FAB: 516 470 2 —(CH₂)₃—CO₂H FAB: 488 471 10 —CH₂CO₂Et —(CH₂)₂—CO₂Et ESI: 574 472 2 —CH₂CO₂H —(CH₂)₂CO₂H FAB: 518

TABLE 52

Ex Syn R⁴ R^(d) Data 473 10  Et —(CH₂)₂—CO₂Et FAB: 446 474 2 —(CH₂)₂—CO₂H FAB: 418 475 1 —CH₂P(O)(OEt)₂ FAB: 496 476 18  —CH₂PO₃H₂ ESI: 440 477 1

FAB: 437 478 10  —CH(Et)₂ —(CH₂)₂—CO₂Et FAB: 488 479 2 —(CH₂)₂—CO₂H FAB: 460 480 10, 9

ESI: 589 481 2

FAB (Neg): 531 482 1 —CH₂P(O)(OEt)₂ FAB: 538 483 18  —CH₂PO₃H₂ FAB: 482 484 1 —CHFP(O)(OEt)₂ FAB: 556 485 18  —CHFPO₃H₂ FAB: 500 486 10  —CF₂P(O)(OEt)₂ FAB: 574 487 18  —CF₂PO₃H₂ FAB: 518 488 1 cPen —CH₂OH FAB: 416 489 10  —(CH₂)₂—CO₂Et FAB: 486 490 2 —(CH₂)₂CO₂H FAB: 458 491 1 —CH₂P(O)(OEt)₂ FAB: 536 492 18  —CH₂PO₃H₂ FAB (Neg): 478 493 494 10  2

—(CH₂)₂—CO₂Et —(CH₂)₂—CO₂H FAB: FAB: 488 460 495 496 10  2

—(CH₂)₂—CO₂Et —(CH₂)₂—CO₂H FAB: FAB: 501 473

TABLE 53

Ex Syn R^(d) Data 497 1 —CH(Me)—nPr ESI: 456 498 1 —C(Me)₂—nPr ESI: 470 499 1 —C(Me)₂—nBu ESI: 484 500 1

ESI: 426 501 1 —CH₂CF₃ ESI: 468 502 1 —CH₂CH(Me)CF₃ ESI: 496 503 1 —CH₂OH ESI: 416 504 1 —CH₂OEt ESI: 444 505 1 —CH₂CN ESI: 425 506 1

ESI: 488 507 1, 2 —(CH₂)₂—CO₂H ESI: 458 508 1 —(CH₂)₃—CO₂Et ESI: 500 509 1, 2

ESI: 486 510 1, 2

ESI: 500 511 1, 2

ESI: 514 512 1, 2

ESI: 514 513 1, 2

ESI: 456 514 1, 2

ESI: 550

TABLE 54 515 1,2

ESI: 621 516 1,2

ESI: 607 517 1,2

ESI: 577 518 1,2

ESI: 607 519 1,2

ESI: 621 520 1,2

ESI: 621 521 1,2

ESI: 621 522 1,2

ESI: 540 523 1,2

ESI: 540 524 1,2

ESI: 554

TABLE 55 525 1,2

ESI: 554 526 1,2

ESI: 548 527 1,2

ESI: 548 528 1,2 —CH(Ph)CH₂CO₂H ESI: 534 529 1

ESI: 577 530 1,2

ESI: 569 531 1,2

ESI: 605 532 1

ESI: 410 533 1 cBu ESI: 440 534 1 cPen ESI: 454 535 1 cHex ESI: 468 536 1

ESI: 452 537 1

ESI: 466 538 1

ESI: 516 539 1,2

ESI: 498

TABLE 56 540 1

ESI: 572 541 1,2

ESI: 512 542 1,2

ESI: 512 543 1,2

ESI: 512 544 1,2

ESI: 510 545 1 —CH₂-cPen ESI: 468 546 1

ESI: 466 547 1,2

ESI: 526 548 1

ESI: 476 549 1

ESI: 480 550 1

ESI: 480 551 1

ESI: 478 552 1

ESI: 478 553 1

ESI: 494

TABLE 57 554 1

ESI: 494 555 1

ESI: 508 556 1

ESI: 512 557 1

ESI: 604 558 1

ESI: 550 559 1

ESI: 520 560 1

ESI: 520 561 1

ESI: 505 562 1

ESI: 487 563 1

ESI: 490 564 1,2

ESI: 506 565 1,2

ESI: 551

TABLE 58 566 1

ESI: 540 567 1

ESI: 574 568 1

ESI: 574 569 1

ESI: 538 570 1

ESI: 556 571 1,2

ESI: 582 572 1

ESI: 528 573 1

ESI: 528 574 1

ESI: 542 575 1

ESI: 570 576 1

ESI: 492 577 1

ESI: 506

TABLE 59 578 1 —(CH₂)₄-Ph ESI: 518 579 1

ESI: 526 580 1

ESI: 528 581 1

ESI: 548 582 1

ESI: 556 583 1

ESI: 566 584 1

ESI: 569 585 1

ESI: 542 586 1,2

ESI: 496 587 1,2

ESI: 578 588 1

ESI: 456 589 1

ESI: 469 590 1

ESI: 469

TABLE 60 591 1

ESI: 545 592 1

ESI: 549 593 1

ESI: 565 594 1

ESI: 569 595 1

ESI: 623 596 1

ESI: 627 597 1

ESI: 643 598 1

ESI: 452 599 1

ESI: 466 600 1

ESI: 480 601 1

ESI: 630 602 1

ESI: 452

TABLE 61 603 1

ESI: 466 604 1

ESI: 480 605 1

ESI: 542 606 1

ESI: 451 607 1

ESI: 465 608 1

ESI: 479 609 1

ESI: 479 610 1

ESI: 617 611 1

ESI: 575 612 1

ESI: 668 613 1,2

ESI: 558

TABLE 62 614 1

ESI: 580 615 1

ESI: 466 616 1

ESI: 497 617 1

ESI: 576 618 1

ESI: 596 619 1

ESI: 452 620 1

ESI: 453 621 1

ESI: 467 622 1

ESI: 467 623 1

ESI: 545 624 1

ESI: 546 625 1

ESI: 546

TABLE 63 626 1

ESI: 560 627 1

ESI: 470 628 1

ESI: 463 629 1

ESI: 477 630 1

ESI: 477 631 1

ESI: 497 632 1

ESI: 511 633 1

ESI: 529 634 1

ESI: 569 635 1

ESI: 637 636 1

ESI: 463 637 1,2

ESI: 507 638 1

ESI: 464

TABLE 64 639 1

ESI: 478 640 1

ESI: 479 641 1

ESI: 520 642 1

ESI: 532 643 1

ESI: 546 644 1

ESI: 547 645 1

ESI: 501 646 1

ESI: 515 647 1

ESI: 535 648 1

ESI: 517 649 1

ESI: 531

TABLE 65 650 1

ESI: 561 651 1

ESI: 515 652 1

ESI: 501 653 1

ESI: 518 654 1

ESI: 502 655 1

ESI: 516 656 1

ESI: 516 657 1

ESI: 506 658 1

ESI: 519 659 1

ESI: 531 660 1

ESI: 513

TABLE 66 661 1

ESI: 529 662 1

ESI: 543 663 1

ESI: 513 664 1

ESI: 513 665 1

ESI: 530 666 1

ESI: 544 667 1

ESI: 548 668 1

ESI: 546 669 1

ESI: 546 670 1

ESI: 530

TABLE 67 671 1

ESI: 608 672 1

ESI: 520 673 1

ESI: 689 674 1

ESI: 561 675 1

ESI: 557 676 1

ESI: 468 677 1

ESI: 515 678 1

ESI: 531 679 1

ESI: 545

TABLE 68 680 1

ESI: 529 681 1

ESI: 543 682 1

ESI: 544 683 1,2

ESI: 535 684 1

ESI: 478 685 1

ESI: 532 686 1

ESI: 538 687 1

ESI: 579

TABLE 69

Ex Syn R^(c) Data 688 5

ESI: 484 689 5

ESI: 484 690 5

ESI: 464 691 5

ESI: 492 692 5

ESI: 522 693 5

ESI: 482 694 5,2

ESI: 592 695 5

ESI: 532

TABLE 70 696 5

ESI: 532 697 5

ESI: 531 698 5

ESI: 609 699 5,2

ESI: 599 700 5,2

ESI: 674

TABLE 71

Ex Syn R⁵ Data 701 29 —CH₂OH FAB: 360 702 39 —CHO FAB: 358 703 24

FAB: 428 704 2

FAB: 400

TABLE 72

Ex Syn R⁵ Data 705 29 —CH₂OH FAB: 360 706 39 —CHO FAB: 358 707 24

FAB: 428 708 2

FAB: 400

TABLE 73

Ex Syn R⁵ Data 709 40 —OH FAB: 331 710 27 —OCH₂CO₂Et FAB: 417 711 2 —OCH₂CO₂H FAB: 389 712 71 —CH₂OH FAB: 345 713 39 —CHO FAB: 343

TABLE 74 Ex Data 32 NMR(DMSO-d₆)δ; 1.11-1.48(m, 5H), 1.60-1.68(m, 1H), 1.70-1.84(m, 8H), 1.90- 1.99(m, 2H), 2.08-2.19(m, 2H), 3.48-3.55(m, 1H), 4.98-5.07(m, 1H), 5.45(s, 2H), 6.03- 6.09(m, 1H), 6.72(d, J = 7.4 Hz, 1H), 7.71(d, J = 12.4 Hz, 1H), 7.74(s, 1H) 76 NMR(DMSO-d₆)δ; 1.10-1.23(m, 1H), 1.24-1.48(m, 4H), 1.44(d, J = 6.6 Hz, 6H), 1.58- 1.68(m, 1H), 1.70-1.79(m, 2H), 1.86(quintet, J = 6.9 Hz, 2H), 1.91-2.00(m, 2H), 2.41(t, J = 7.4 Hz, 2H), 3.47-3.58(m, 1H), 3.97(t, J = 6.4 Hz, 2H), 4.89-5.02(m, 1H), 5.92(dd, J = 2.2, 8.3 Hz, 1H), 6.71(d, J = 7.3 Hz, 1H), 7.67(d, J = 12.4 Hz, 1H), 7.74(s, 1H), 12.10(s, 1H) 80 NMR(DMSO-d₆)δ; 1.10-1.24(m, 1H), 1.26-1.51(m, 10H), 1.60-1.69(m, 1H), 1.71- 1.80(m, 2H), 1.91-2.07(m, 3H), 2.09-2.20(m, 1H), 2.43-2.60(m, 2H), 3.53-3.65(m, 1H), 4.50(dd, J = 4.9, 7.3 Hz, 1H), 5.03-5.15(m, 1H), 6.23(dd, J = 2.2, 8.3 Hz, 1H), 6.81(d, J = 7.2 Hz, 1H), 7.74(d, J = 12.3 Hz, 1H), 8.11(s, 1H) 82 NMR(DMSO-d₆)δ; 1.11-1.23(m, 1H), 1.26-1.51(m, 4H), 1.44(d, J = 6.7 Hz, 3H), 1.47(d, J = 6.5 Hz, 3H), 1.48(d, J = 6.5 Hz, 3H), 1.60-1.69(m, 1H), 1.71-1.80(m, 2H), 1.91- 2.00(m, 2H), 3.53-3.64(m, 1H), 4.56(q, J = 6.8 Hz, 1H), 5.02-5.14(m, 1H), 6.23(dd, J = 2.2, 8.3 Hz, 1H), 6.81(d, J = 7.3 Hz, 1H), 7.75(d, J = 12.3 Hz, 1H), 8.08(s, 1H), 15.23(brs, 1H) 87 NMR(DMSO-d₆)δ; 1.11-1.46(m, 12H), 1.58-1.67(m, 1H), 1.68-1.77(m, 2H), 1.85- 1.95(m, 2H), 2.92-3.03(m, 1H), 3.46-3.57(m, 1H), 4.62(brs, 1H), 4.84-4.95(m, 1H), 6.16- 6.28(m, 1H), 6.64-6.71(m, 1H), 6.75-6.96(m, 1H), 7.19-7.39(m, 5H), 7.71(d, J = 12.1 Hz, 1H) 95 NMR(DMSO-d₆)δ; 0.74(t, J = 7.2 Hz, 6H), 1.12-1.53(m, 5H), 1.58-2.00(m, 9H), 3.52- 3.68(m, 1H), 4.58(s, 2H), 4.67-4.81(m, 1H), 6.08(d, J = 7.8 Hz, 1H), 6.85(d, J = 6.8 Hz, 1H), 7.72(dd, J = 1.1, 12.3 Hz, 1H), 7.97(s, 1H) 106 NMR(DMSO-d₆)δ; 1.11-1.23(m, 1H), 1.25-1.48(m, 4H), 1.60-1.68(m, 1H), 1.71- 1.99(m, 12H), 2.09-2.20(m, 2H), 2.40(t, J = 7.3 Hz, 2H), 3.45-3.56(m, 1H), 3.96(t, J = 6.4 Hz, 2H), 4.96-5.05(m, 1H), 5.95(dd, J = 1.9, 8.2 Hz, 1H), 6.70(d, J = 7.3 Hz, 1H), 7.63(s, 1H), 7.66(d, J = 12.5 Hz, 1H), 12.09(s, 1H) 114 NMR(DMSO-d₆)δ; 1.11-1.56(m, 8H), 1.59-1.78(m, 7H), 1.88-1.96(m, 2H), 1.97- 2.08(m, 2H), 3.00(dd, J = 10.4, 14.3 Hz, 1H), 3.49-3.58(m, 1H), 4.72(dd, J = 3.4, 10.4 Hz, 1H), 4.96(quintet, J = 7.2 Hz, 1H), 6.32(d, J = 7.3 Hz, 1H), 6.71(d, J = 7.3 Hz, 1H), 6.88(s, 1H), 7.26- 7.41(m, 5H), 7.73(d, J = 12.2 Hz, 1H), 16.29(brs, 1H) 125 NMR(DMSO-d₆)δ; 1.12-1.24(m, 1H), 1.26-1.48(m, 4H), 1.43(d, J = 6.8 Hz, 3H), 1.61- 1.69(m, 1H), 1.72-2.00(m, 10H), 2.13-2.25(m, 2H), 3.50-3.61(m, 1H), 4.58(q, J = 6.8 Hz, 1H), 5.12(quintet, J = 6.8 Hz, 1H), 6.22(dd, J = 2.1, 8.2 Hz, 1H), 6.78(d, J = 7.3 Hz, 1H), 7.73(d, J = 12.3 Hz, 1H), 7.92(s, 1H), 14.87(brs, 1H) 146 NMR(DMSO-d₆)δ; 1.12-1.24(m, 1H), 1.25-1.48(m, 4H), 1.60-2.02(m, 15H), 2.09- 2.21(m, 2H), 2.25-2.33(m, 2H), 3.45-3.56(m, 1H), 3.95(s, 2H), 5.01(quintet, J = 6.9 Hz, 1H), 5.95(dd, J = 1.9, 8.2 Hz, 1H), 6.70(d, J = 7.3 Hz, 1H), 7.60(s, 1H), 7.67(d, J = 12.5 Hz, 1H), 11.60- 12.40(br, 1H) 196 NMR(DMSO-d₆)δ; 0.74(t, J = 7.3 Hz, 6H), 1.10-1.23(m, 1H), 1.24-1.36(m, 2H), 1.37- 1.50(m, 2H), 1.61-1.79(m, 5H), 1.81-1.97(m, 4H), 3.53-3.66(m, 1H), 4.69-4.80(m, 1H), 6.04(d, J = 7.0 Hz, 1H), 6.82(d, J = 7.0 Hz, 1H), 7.29(d, J = 4.0 Hz, 1H), 7.67(d, J = 12.2 Hz, 1H), 7.71(d, J = 4.2 Hz, 1H), 8.55(s, 1H), 8.62(s, 1H), 11.30-11.70(br, 1H)

TABLE 75 202 NMR(DMSO-d6)δ; 1.12-1.25(m, 1H), 1.26-1.49(m, 4H), 1.60-1.68(m, 1H), 1.71- 1.89(m, 10H), 1.93-2.01(m, 2H), 2.13-2.26(m, 2H), 2.39(t, J = 6.5 Hz, 2H), 3.47-3.56(m, 1H), 5.05-5.13(m, 1H), 5.93(d, J = 6.2 Hz, 1H), 6.72(d, J = 7.3 Hz, 1H), 7.14(t, J = 5.7 Hz, 1H), 7.67(d, J = 12.4 Hz, 1H), 8.07(s, 1H), 8.92(s, 1H), 12.19(brs, 1H) 233 NMR(DMSO-d6)δ; 0.75(t, J = 7.3 Hz, 6H), 1.11-1.51(m, 5H), 1.61-1.79(m, 5H), 1.81- 1.99(m, 4H), 2.68(t, J = 6.7 Hz, 2H), 3.53-3.64(m, 1H), 4.68-4.78(m, 1H), 5.98(d, J = 6.8 Hz, 1H), 6.82(d, J = 7.2 Hz, 1H), 7.70(d, J = 12.2 Hz, 1H), 8.91(s, 1H), 9.15(s, 1H), 12.09(brs, 1H) 261 NMR(CD3OD)δ; 0.84(t, J = 7.3 Hz, 6H), 1.26-1.41(m, 3H), 1.44-1.58(m, 2H), 1.66- 1.76(m, 1H), 1.79-2.02(m, 8H), 2.04-2.13(m, 2H), 2.69-2.79(m, 2H), 3.46-3.58(m, 1H), 4.60- 4.71(m, 1H), 6.80(d, J = 6.8 Hz, 1H), 7.85(d, J = 12.4 Hz, 1H), 9.05(s, 1H) 271 NMR(DMSO-d₆)δ; 1.11-1.24(m, 1H), 1.26-1.49(m, 4H), 1.61-1.68(m, 1H), 1.72- 1.89(m, 10H), 1.93-2.00(m, 2H), 2.15-2.29(m, 4H), 2.45(t, J = 7.4 Hz, 2H), 3.48-3.59(m, 1H), 5.06-5.14(m, 1H), 6.05(dd, J = 2.2, 8.3 Hz, 1H), 6.75(d, J = 7.4 Hz, 1H), 7.69(d, J = 12.3 Hz, 1H), 9.03(s, 1H), 9.06(s, 1H), 12.05(brs, 1H) 297 NMR(DMSO-d₆)δ; 0.27-0.32(m, 2H), 0.47-0.54(m, 2H), 1.10-1.20(m, 1H), 1.68- 1.80(m, 2H), 1.81-1.99(m, 4H), 2.13-2.25(m, 2H), 3.18(t, J = 6.2 Hz, 2H), 5.10(quintet, J = 7.0 Hz, 1H), 6.52-6.57(m, 1H), 6.85(d, J = 7.3 Hz, 1H), 7.19(d, J = 15.6 Hz, 1H), 7.55(d, J = 15.6 Hz, 1H), 7.73(d, J = 12.3 Hz, 1H), 8.24(s, 1H), 11.85(brs, 1H) 321 NMR(DMSO-d₆)δ; 1.11-1.47(m, 5H), 1.49(d, J = 6.6 Hz, 6H), 1.60-1.69(m, 1H), 1.71- 1.79(m, 2H), 1.91-1.99(m, 2H), 3.52-3.63(m, 1H), 5.02(quintet, J = 6.6 Hz, 1H), 6.11(dd, J = 2.4, 8.4 Hz, 1H), 6.81(d, J = 7.3 Hz, 1H), 7.18(d, J = 15.4 Hz, 1H), 7.55(d, J = 15.6 Hz, 1H), 7.73(d, J = 12.4 Hz, 1H), 8.34(s, 1H), 11.84(s, 1H) 324 NMR(DMSO-d₆)δ; 1.09-1.23(m, 1H), 1.25-1.52(m, 4H), 1.45(d, J = 6.5 Hz, 6H), 1.59- 1.68(m, 1H), 1.70-1.79(m, 2H), 1.89-2.00(m, 2H), 3.51-3.62(m, 1H), 5.01(quintet, J = 6.5 Hz, 1H), 6.15(dd, J = 2.1, 8.3 Hz, 1H), 6.80(d, J = 7.1 Hz, 1H), 7.45(s, 2H), 7.62(t, J = 7.5 Hz, 1H), 7.67-7.75(m, 2H), 7.95(d, J = 7.2 Hz, 1H), 8.30(s, 1H), 12.04(brs, 1H) 354 NMR(DMSO-d₆)δ; 0.75(t, J = 7.1 Hz, 6H), 1.11-1.51(m, 5H), 1.60-2.00(m, 9H), 3.56- 3.66(m, 1H), 4.68-4.78(m, 1H), 6.08(d, J = 7.4 Hz, 1H), 6.87(d, J = 6.8 Hz, 1H), 7.22(d, J = 15.6 Hz, 1H), 7.56(d, J = 15.6 Hz, 1H), 7.73(d, J = 12.7 Hz, 1H), 8.28(s, 1H), 11.85(brs, 1H) 378 NMR(DMSO-d₆)δ; 1.11-1.24(m, 1H), 1.25-1.47(m, 4H), 1.60-1.68(m, 1H), 1.71- 1.91(m, 8H), 1.92-2.00(m, 2H), 2.08-220(m, 2H), 2.46(t, J =7.2 Hz, 2H), 2.62(t, J =7.2 Hz, 2H), 3.44-3.56(m, 1H), 4.99(quintet, J = 6.6 Hz, 1H), 5.93(dd, J = 2.1, 8.2 Hz, 1H), 6.71(d, J = 7.3 Hz, 1H), 7.64(d, J = 12.5 Hz, 1H), 7.71(s, 1H), 12.11(s, 1H) 380 NMR(DMSO-d₆)δ; 1.11-1.24(m, 1H), 1.27-1.48(m, 4H), 1.61-1.69(m, 1H), 1.69- 1.80(m, 4H), 1.81-1.91(m, 2H), 1.92-2.02(m, 4H), 2.13-2.23(m, 2H), 3.49-3.62(m, 1H), 5.07(quintet, J = 7.1 Hz, 1H), 6.15(dd, J = 2.3, 8.2 Hz, 1H), 6.80(d, J = 7.2 Hz, 1H), 7.18(d, J = 15.6 Hz, 1H), 7.55(d, J = 15.6 Hz, 1H), 7.72(d, J = 12.3 Hz, 1H), 8.22(s, 1H), 11.85(brs, 1H)

TABLE 76

No R^(b) 1 —CH(Et)CO₂H 2 —CH(nPr)CO₂H 3 —CH(iPr)CO₂H 4

5

6

7 —CH₂C(O)NH₂ 8 —CH₂CH(OH)CH₂CO₂H 9 —(CH₂)₂—CH(OH)CO₂H 10 —CH₂CH(Me)CH₂CO₂H 11 —(CH₂)₂—CH(Me)CO₂H 12 —(CH₂)₂—C(Me)₂CO₂H 13 —CH(CO₂H)—(CH₂)₂—CO₂Et 14 —CH(CO₂Et)—(CH₂)₂—CO₂H 15 —CH₂C(O)NH—S(O)₂Me 16 —CH₂C(O)NH—S(O)₂Ph 17

18

19 —CH(Me)—(CH₂)₂—CO₂H 20 —(CH₂)₃—PO₃H₂ 21

TABLE 77

No R^(b) 22 —CH(Et)CO₂H 23 —CH(nPr)CO₂H 24 —CH(iPr)CO₂H 25

26

27

28 —CH₂C(O)NH₂ 29 —CH(Me)C(O)NH₂ 30 —CH₂CH(OH)CH₂CO₂H 31 —(CH₂)₂—CH(OH)CO₂H 32 —CH₂CH(Me)CH₂CO₂H 33 —(CH₂)₂—CH(Me)CO₂H 34 —(CH₂)₂—C(Me)₂CO₂H 35 —CH(CO₂H)—(CH₂)₂—CO₂Et 36 —CH(CO₂Et)—(CH₂)₂—CO₂H 37 —CH₂C(O)NH—S(O)₂Me 38 —CH(Me)C(O)NH—S(O)₂Me 39 —CH₂C(O)NH—S(O)₂Ph 40 —CH(Me)C(O)NH—S(O)₂Ph 41

42

43 —CH(Me)CO₂H 44 —CH(Bn)CO₂H 45 —(CH₂)₃—CO₂H

TABLE 78 46 —CH(CO₂H)—(CH₂)₂—CO₂H 47 —CH(Me)—(CH₂)₂—CO₂H 48 —(CH₂)₃—PO₃H₂ 49

TABLE 79

No R^(b) 50 —CH(nPr)CO₂H 51

52

53

54 —CH₂C(O)NH₂ 55 —CH(Me)C(O)NH₂ 56 —CH₂CH(OH)CH₂CO₂H 57 —(CH₂)₂—CH(OH)CO₂H 58 —(CH₂)₂—C(Me)₂CO₂H 59 —CH(CO₂H)—(CH₂)₂—CO₂Et 60 —CH(CO₂Et)—(CH₂)₂—CO₂H 61 —CH₂C(O)NH—S(O)₂Me 62 —CH(Me)C(O)NH—S(O)₂Me 63 —CH₂C(O)NH—S(O)₂Ph 64 —CH(Me)C(O)NH—S(O)₂Ph 65

TABLE 80

No R⁵ 66

67 —(CH₂)₃—CO₂H 68 —CH₂OCH₂CO₂H 69

70 —NHC(O)CH₂CH(Me)CO₂H 71 —NHC(O)—(CH₂)₂—CH(Me)CO₂H 72 —NHC(O)—(CH₂)₂—C(Me)₂CO₂H 73

74

75

76

77 —(CH₂)₂—CO₂H 78 —NHC(O)—(CH₂)₂—PO₃H₂ 79 —NHC(O)CH(Me)CO₂H

TABLE 81

No R⁵ 80

81 —(CH₂)₃—CO₂H 82 —CH₂OCH₂CO₂H 83

84 —NHC(O)CH₂CH(Me)CO₂H 85 —NHC(O)—(CH₂)₂—CH(Me)CO₂H 86 —NHC(O)—(CH₂)₂—C(Me)₂CO₂H 87

88

89

90

TABLE 82

No R⁵ 91

92 —(CH₂)₃—CO₂H 93 —CH₂OCH₂CO₂H 96 —NHC(O)CH₂CH(Me)CO₂H 97 —NHC(O)—(CH₂)₂—CH(Me)CO₂H 98 —NHC(O)—(CH₂)₂—C(Me)₂CO₂H 99

100

101

102 —NHC(O)CH(Me)CO₂H

TABLE 83

No

R⁵ 103 104 105 106 107

—OCH(CH₃)CO₂H —OCH(CH₂Ph)CO₂H

—NHC(O)—(CH₂)₃CO₂H —NHC(O)—(CH₂)₂CO₂H 108 109 110 111 112 113

—OCH₂CO₂H —OCH(CH₃)CO₂H —OCH(CH₂Ph)CO₂H

—NHC(O)—(CH₂)₃CO₂H —NHC(O)—(CH₂)₂CO₂H 114 115 116 117 118 119

—OCH₂CO₂H —OCH(CH₃)CO₂H —OCH(CH₂Ph)CO₂H

—NHC(O)—(CH₂)₃CO₂H —NHC(O)—(CH₂)₂CO₂H 120 121 122 123 124 125

—OCH₂CO₂H —OCH(CH₃)CO₂H —OCH(CH₂Ph)CO₂H

—NHC(O)—(CH₂)₃CO₂H —NHC(O)—(CH₂)₂CO₂H 126 127 128 129 130 131

—OCH₂CO₂H —OCH(CH₃)CO₂H —OCH(CH₂Ph)CO₂H

—NHC(O)—(CH₂)₃CO₂H —NHC(O)—(CH₂)₂CO₂H

INDUSTRIAL APPLICABILITY

Since the quinolone derivatives of the present invention or salts thereof have excellent platelet aggregation inhibitory activity or P2Y12 inhibitory activity, they are useful as a pharmaceutical, particularly a platelet aggregation inhibitor or a P2Y12 inhibitor. Accordingly, the compounds of the present invention are useful as a preventive and/or therapeutic agent for a circulatory organ system disease closely related to the thrombus formation by platelet aggregation, such as unstable angina, acute myocardial infarction and its secondary prevention, re-obstruction and re-stricture after hepatic artery bypass surgery, PTCA operation or stent indwelling operation, hepatic artery thrombolysis acceleration and re-obstruction prevention and the like ischemic diseases; transient cerebral ischemic attack (TIA) cerebral infarction, subarachnoid hemorrhage (vasospasm) and the like cerebrovascular accidents; chronic arterial occlusive disease and the like peripheral arterial diseases; and the like, and as an auxiliary agent at the time of cardiac surgical operation or vascular surgical operation. 

1. A quinolone derivative represented by a formula (I) or a pharmaceutically acceptable salt thereof

[symbols in the formula represent the following meanings, R¹: cycloalkyl or lower alkylene-cycloalkyl, wherein cycloalkyl in R¹ may be substituted, R²: —H or halogen, R³: —H, halogen, —OR⁰ or —O-lower alkylene-aryl, R⁰: the same or different from each other and each represents —H or lower alkyl, R⁴: lower alkyl, halogeno-lower alkyl, lower alkylene-cycloalkyl, cycloalkyl or heterocyclic group, wherein cycloalkyl and heterocyclic group in R⁴ may respectively be substituted, R⁵: —NO₂, —CN, lower alkyl, lower alkenyl, halogeno lower alkenyl, -L-R^(a), —C(O)R⁰, —O—R^(b), —N(R⁶)₂, lower alkylene-N(R⁶)(R^(c)), —N(R⁶)C(O)—R^(d), lower alkylene-N(R⁶)C(O)—R^(d), lower alkylene-N(R⁰)C(O)O-lower alkyl, —N(R⁰)C(O)N(R⁰)—R^(e), lower alkylene-N(R⁰)C(O)N(R⁰)—R^(e), —N(R⁰)S(O)₂N(R⁰)C(O)—R^(d), —CH═NOH, cycloalkyl, heterocyclic group, (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl or (4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl, wherein cycloalkyl and heterocyclic group in R⁵ may respectively be substituted, R⁶: H, lower alkyl, lower alkylene-CO₂R⁰ or lower alkylene-P(O)(OR^(p))₂, wherein lower alkylene in R⁶ may be substituted, L: lower alkylene or lower alkenylene which may respectively be substituted R^(a): —OR⁰, —CN, —O-lower alkylene-aryl, —O-lower alkylene-CO₂R⁰, —C(O)R⁰, —CO₂R⁰, —C(O)NHOH, —C(O)N(R⁶)₂, —C(O)N(R⁰)-aryl, —C(O)N(R⁰)—S(O)₂-lower alkyl, —C(O)N(R⁰)—S(O)₂-aryl, —C(O)N(R^(e))—S(O)₂-heterocyclic group, —NH₂OH, —OC(O)R⁰, —OC(O)-halogeno-lower alkyl, —P(O)(OR^(p))₂, aryl or heterocyclic group, wherein aryl and heterocyclic group in R^(a) may be substituted, R^(P): R⁰, lower alkylene-OC(O)-lower alkyl, lower alkylene-OC(O)-cycloalkyl, lower alkylene-OC(O)O-lower alkyl, lower alkylene-OC(O)O-cycloalkyl, or lower alkylene-heterocyclic group, wherein heterocyclic group in R^(p) may be substituted, R^(b): H, cycloalkyl, aryl, heterocyclic group, lower alkylene-R^(ba) or lower alkenylene-R^(ba), wherein lower alkylene, lower alkenylene, cycloalkyl, aryl and heterocyclic group in R^(b) may be substituted, R^(ba): —OR⁰, —O—Si(lower alkyl)₃, —CO₂R⁰, —C(O)NHOH, —C(O)N(R⁰)₂, —C(O)N(R⁰)—S(O)₂-lower alkyl, —C(O)N(R⁰)—S(O)₂-aryl, —C(NH₂)═NOH, —C(NH₂)═NO—C(O)R⁰, —C(NH₂)═NO—C(O)-lower alkylene-C(O)R⁰, —CO₂-lower alkylene-aryl, —P(O)(OR^(p))₂, —C(O)R⁰, —C(O)-aryl, cycloalkyl, aryl or heterocyclic group, wherein aryl and heterocyclic group in R^(ba) may be substituted, R^(c): H, lower alkyl, lower alkylene-OR⁰, lower alkylene-CO₂R⁰, lower alkylene-C(O)NHOH, lower alkylene-C(O)N(R⁰)₂, lower alkylene-P(O)(OR^(p))₂, lower alkylene-aryl, lower alkylene-heterocyclic group, aryl or heterocyclic group, wherein lower alkylene, aryl and heterocyclic group in R^(c) may be substituted, R^(d): C₁₋₇ alkyl, lower alkenyl, halogeno-lower alkyl, lower alkylene-R^(da), lower alkenylene-R^(da), cycloalkyl, aryl or heterocyclic group, wherein lower alkylene, lower alkenylene, cycloalkyl, aryl and heterocyclic group in R^(d) may be substituted, R^(da): —CN, —OR⁰, —OC(O)R⁰, —O-lower alkylene-CO₂R⁰, —O-aryl, —CO₂R⁰, —C(O)NHOH, —C(O)N(R⁰)₂, —CO₂-lower alkylene-N(R⁰)₂, —P(O)(OR^(p))₂, —N(R⁶)₂, —N(R⁰)C(O)R⁰, —C(O)N(R⁰)-aryl, —C(O)N(R⁰)-(lower alkylene which may be substituted with —CO₂R⁰)-aryl, —N(R⁰)C(O)-aryl, —N(R⁰)C(O)—OR⁰, —N(R⁰)C(O)—O-lower alkylene-aryl, —N(R⁰)S(O)₂-aryl, —S-heterocyclic group, —C(O)N(R⁰)-heterocyclic group, —N(R⁰)C(O)-heterocyclic group, cycloalkyl, aryl or heterocyclic group, wherein cycloalkyl, aryl and heterocyclic group in R^(da) may be substituted, R^(e): lower alkylene-CO₂R⁰, lower alkylene-C(O)NHOH, lower alkylene-C(O)N(R⁰)₂, lower alkylene-heterocyclic group, aryl, heterocyclic group, —S(O)₂-aryl or —S(O)₂-heterocyclic group, wherein aryl and heterocyclic group in R^(e) may be substituted, X: CH or N, A: C(R⁷) or N, R⁷: —H and lower alkyl, or R⁴ and R⁷ may together form lower alkylene which may be substituted, with the proviso that 7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile is excluded.
 2. The compound described in claim 1, wherein X is CH.
 3. The compound described in claim 2, wherein R³ is —H, —OH or —F.
 4. The compound described in claim 3, wherein A is CH.
 5. The compound described in claim 4, wherein R¹ is cyclohexyl or cyclopropylmethyl.
 6. The compound described in claim 5, wherein R² is —F.
 7. The compound described in claim 6, wherein R⁴ is lower alkyl or cycloalkyl.
 8. The compound described in claim 7, wherein R⁵ is —N(R⁰)C(O)-lower alkylene-CO₂R⁰, lower alkylene-CO₂R⁰, lower alkenylene-CO₂R⁰, —O-lower alkylene-CO₂R⁰, —O-(lower alkylene which may be substituted with —CO₂R⁰)-aryl or —O-lower alkenylene-CO₂R⁰.
 9. The compound described in claim 1, which is selected from the group consisting of 4-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-4-oxobutanoic acid, 5-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]amino}-5-oxopentanoic acid, (2E)-3-[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]acrylic acid, (2S)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-phenylpropanoic acid, (2E)-3-[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]acrylic acid, (2S)-2-{[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-phenylpropanoic acid, (2S)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}propanoic acid, and (2S)-2-{[7-(cyclohexylamino)-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinolin-3-yl]oxy}propanoic acid, or a pharmaceutically acceptable salt thereof.
 10. A pharmaceutical composition which comprises the compound or a pharmaceutically acceptable salt thereof described in claim 1, and a pharmaceutically acceptable carrier.
 11. The pharmaceutical composition described in claim 10, which is a platelet aggregation inhibitor.
 12. The pharmaceutical composition described in claim 10, which is a P2Y12 inhibitor.
 13. Use of the compound described in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a platelet aggregation inhibitor or a P2Y12 inhibitor. 